Ronald G. GILL Page 25

CURRICULUM VITAE

Ronald G. Gill, PhD University of Colorado, Denver US Citizen Barbara Davis Center Married / 4 children 1775 Aurora Ct., Box F-528, M20 Aurora, CO 80045

Phone 303.724.5321 Fax 303.724.7624 E-mail [email protected]

EDUCATION

1977/11-1985/02 PhD Biology University of California, Los Angeles Thesis: The effect of exogenous fatty acids on cell- mediated cytolysis (Supervisor: Dr. W.R. Clark)

1972/09-1976/08 BA Biology University of California, Los Angeles

PROFESSIONAL APPOINTMENTS

2009/11-present Scientific Director, Colorado Center for Transplantation Care, Research and Education (CCTCARE) 2002/11-present Professor of Surgery and Immunology, University of Colorado, Denver 2009/01-2009/10 Adjunct Professor, Department of Surgery, U of Alberta, Canada 2007/04-2009/10 Scientific Director, Alberta Diabetes Institute, U of Alberta, Canada 2007/04-2009/10 Dr. Charles A. Allard Chair in Diabetes Research, Alberta Diabetes Institute, U of Alberta, Canada 2007/04-2009/10 Professor, Department of Medical Microbiology and Immunology, U of Alberta, Canada 2002/03-2007/03 Professor, Department of Medicine and Department of Immunology, U of Colorado Health Sciences Center 2001/07-2007/03 Director, Rocky Mountain Islet Transplantation Program, NCRR Islet Cell Resources Program 1996/09-2007/03 Director, Transplant Immunology Program, U of Colorado Health Sciences Center 1992/10-2007/03 Member, Barbara Davis Center for Childhood Diabetes, U of Colorado Health Sciences Center 1996/08-2002/02 Associate Professor, Department of Immunology, U of Colorado Health Sciences Center 1993/06-1996/10 Acting Research Director, Barbara Davis Center for Childhood Diabetes, U of Colorado Health Sciences Center

Updated: January 16, 2011 Page 1 Ronald G. GILL Page 2

1994/10-1996/07 Assistant Professor, Department of Immunology, U of Colorado Health Sciences Center 1989/06-1994/09 Assistant Professor, Department of Microbiology and Immunology, U of Colorado Health Sciences Center 1989/10-1992/09 Associate Member, Barbara Davis Center for Childhood Diabetes, U of Colorado Health Sciences Center 1989/09-1991/08 Instructor, Department of Microbiology and Immunology, U of Colorado Health Sciences Center 1984/09-1989/08 Postdoctoral Fellow, Barbara Davis Center for Childhood Diabetes, U of Colorado Health Sciences Center (Supervisor: Dr. K. Lafferty) 1982/09-1984/08 Teaching Fellow, Department of Biology, U of California, Los Angeles 1980/09-1982/08 Teaching Assistant, Department of Biology, U of California, Los Angeles

HONORS / AWARDS

2008/07-2015/06 Scientist Award, Alberta Heritage Foundation for Medical Research 2008 Mary Jane Kugel Award, JDRF Medical Science Review Committee 2004 Mary Jane Kugel Award, JDRF Medical Science Review Committee 2000 Chancellors Award for Teaching Excellence, Graduate School, U of Colorado Health Sciences Center 1991/07-1994/06 Career Development Award (#291292), Juvenile Diabetes Foundation 1990 Travel Award, The Transplantation Society 1988 Travel Award, The Transplantation Society 1988-1990 Fellowship Award (#388180), Juvenile Diabetes Foundation 1986-1988 NIH Traineeship Award (#5 T32 AI-07035)

DEPARTMENTAL / UNIVERSITY COMMITTEES

2009/01-2009/10 External Member, Research Committee, Department of Medicine, U of Alberta 2008/10-2009/10 Member, Security Task Force Committee, Faculty of Medicine & Dentistry, U of Alberta 2008/02-2009/10 Executive Committee Member, Faculty Animal Utilization Committee, Faculty of Medicine & Dentistry, U of Alberta 2007/09-2009/10 Member, Muttart Diabetes Research & Training Centre, U of Alberta 2007/04-2009/10 Alberta Diabetes Institute, Faculty of Medicine and Dentistry, U of Alberta o Chair – ADI Research Coordinating Committee (2007/04-present) o Chair – ADI Annual Research Day Organizing Committee (2007/04-present) o Member – ADI Board of Directors (2007/04-present) 2007/09-2008/08 Member, Search and Selection Committee, Medical Microbiology and Immunology, U of Alberta 2008/05 Podium Judge, Tom Williams Surgical Research Day, U of Alberta (May 9, 2008) 2000/06-2007/03 Chair, Animal Resource Advisory Committee, U of Colorado Health Sciences Center 2006/01-2007/02 Faculty Search Committee, Department of Surgery, U of Colorado Health Sciences Center 1999/09-2007/03 Faculty Search Committee, Department of Immunology, U of Colorado Health Sciences Center 1999/09-2007/03 Faculty Search Committee, Barbara Davis Center for Childhood Diabetes, U of Colorado Health Sciences Center

Updated: January 16, 2011 Ronald G. GILL Page 3

1997/02-2007/03 Co-Director, Univ. of Colorado Association of Transplant Physicians and Surgeons 1994/09-2007/03 Member, Animal Resource Advisory Committee, U of Colorado Health Sciences Center 1995/09-2007/03 Medical Scientist Training Program (MSTP) Faculty, U of Colorado Health Sciences Center 1994/09-1997/12 Immunology Seminar Committee, U of Colorado Health Sciences Center 1994/09-1996/06 Transplantation Immunology Search Committee, U of Colorado Health Sciences Center 1997/04 Ad Hoc, HUI/SBR Grant Review Committee 1997 & 1998 Immunology graduate student recruiting lectures Graduate School Recruiting (1997, 1998, 1999, 2000, 2001, 2002) 1993 Member, Organizing Committee, Denver T Cell Symposium, U of Colorado Health Sciences Center

NATIONAL AND INTERNATIONAL COMMITTEES

2009-present Chair, Scientific Advisory Board, Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) 2009-present External Evaluation Committee, NIDDK Integrated Islet Distribution Program 2009 Chair, American Society of Transplantation, Basic Science Advisory Committee 2009-present DSMB member, NIDDK Clinical Islet Transplantation Consortium 2010-present Member, The Transplantation Society Basic Science Committee 2009/01-2013/12 Medical Review Panel, The Gairdner Foundation (Canada) 2008/03-2009/10 Board of Directors, Alberta Diabetes Foundation 2007/07-2009/10 Research Portfolio Advisory Committee (Immunology), Juvenile Diabetes Research Foundation 2007/07-2009/10 Scientific Sessions Planning Committee, American Diabetes Association 2006/01-present Network Steering Committee, NIH Immune Tolerance Network 2008/04 INVITED PARTICIPANT: Diabetes Policy Review Meeting, Government of Canada, Calgary, Alberta (April 11, 2008) 2003/01-2007/12 Xenotransplantation Advisory Committee: National Institutes of Health 1995-1998 Councilor, Cell Transplant Society

GRANT REVIEWING

2008/06 Chair, JDRF Review “Roles of Innate Immunity and Inflammation in Type 1 Diabetes” (New York, NY / June 4, 2008) 2002-2006 Steering Committee, NCRR Islet Cell Resources Center, Rocky Mountain Islet Transplantation Program, U of Colorado Health Sciences Center 2003-2004 Research Executive Committee, Juvenile Diabetes Foundation International 1998/03-2003/02 Medical Advisory Committee, Alberta Foundation for Diabetes Research 2003 Chair, Organizing Committee, Basic Sciences Symposium, International Transplantation Society, Keystone, CO, 2003 2002 Member, Organizing Committee, Denver Autoimmunity Workshop 2001 Chair, Organizing Committee. 10th Anniversary Congress of the Cell Transplant Society, Keystone, CO (October 14-17, 2001) 2000 Member, International Organizing Committee, Artificial Organs III, United Engineering Foundation. Davos, Switzerland, 2000

1999 Member, International Organizing Committee. International Pancreas and Islet Transplant Society Congress. Sydney, Australia, 1999

JOURNAL EDITORIAL BOARDS

2005-present Associate Editor, American Journal of Transplantation 1994-present Editorial Board, Transplantation 1995-present Editorial Board, Transplant Immunology 1998-2000 Editorial Board, Diabetes

JOURNAL REVIEWING Scientific Manuscripts o Regular Reviewer  Journal of Immunology o Ad Hoc Reviewer  American Journal of Transplantation  Blood  Diabetes  Diabetologia  Journal of Autoimmunity  Journal of Clinical Investigation  Journal of Experimental Medicine  Nature  Nature Medicine  Proceedings of the National Academy of Science (USA)  Science  Xenotransplantation

MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS

2001-present American Society of Transplantation 1995-present Xenotransplantation Society 1993-present International Pancreas and Islet Transplantation Association 1991-present Cell Transplant Society – Founding Member 1991-present American Diabetes Association 1990-present American Association of Immunologists 1989-present The Transplantation Society 1987-1995 Professional Member, Juvenile Diabetes Foundation International

Grant and Abstract Review Committees - Chairs/Co-Chairs

Grant Reviewing

2006/08-2008/07 Chair, NIH/CSR “Transplantation, Tolerance, and Tumor Immunology Study Section” (National Institutes of Health Center for Scientific Review) 2000-2002 Chair, NIH/CSR “Immunological Sciences Study Section” (National Institutes of Health Center for Scientific Review)

2008/12 Chair, JDRF Program Project Site Visit Member “Langer Evaluation”, Cambridge, MA (December 17, 2008) 2005 Chair, NIH Special Emphasis Review Panel, ZAI1 TH0I (MS) (Feb 17/05) 2005 Chair, NIH Special Emphasis Review Panel, ZAI1 TH-1 (M2) (Feb 17/05) 2004 Chair, NIH: Chair, Special Emphasis Review Panel, ZDK1 GRB-7 (M3)P (Apr 28/04) 1999/07 Chair, JDFI Special Grant Site Visit Team, Chicago, IL

Abstract Reviewing 2008/09-2009/02 Co-Chair, Abstract Review Committee, 2009 American Transplant Congress (Boston, MA, May 30-June 3, 2009) 2007/09-2008/02 Co-Chair, Abstract Review Committee, 2008 American Transplant Congress (Toronto, ON, May 31-June 4, 2008)

Grant Review Committees and Ad hoc Reviewing

2003/08-2008/07 Member, NIH/CSR “Transplantation, Tolerance, and Tumor Immunology Study Section” (National Institutes of Health Center for Scientific Review) 2005/07-2008/06 Member, JDRF Medical Review Committee (Autoimmunity) 2001-2003 Member, JDRF Medical Review Committee 2010 Ad hoc reviewer: NIH CSR SEP ZRG1 IMM-C program project review

2000-209 Ad hoc: Canadian Diabetes Association grant reviewing 1995-present Alberta Heritage Foundation for Medical Research (ad hoc) 2005 NIDDK: Islet Transplantation DSMB (Sept 19-20/05) 2004 NIH: Special Emphasis Panel, ZRG1 ALY 02 (Apr 19/04) 2004 NIH: Ad Hoc Reviewer, SAT Study Section (Feb 4/04) 2002 NIH: Special Emphasis Panel ADK1 GRB 8 (01) (Aug 7/02) 2002 NIH: Special Emphasis Panel ZG1 IMS (02) (Apr 19/02) 1997-2002 NIH/CSR Immunological Sciences Study Section 2001 NASA/NIDDK/JDRF/NCRR : Advisor for RFA development for Islet Encapsulation 2001 JDFI: Ad Hoc Reviewer, Juvenile Diabetes Research Foundation 2000 JDFI: Ad Hoc Reviewer, Juvenile Diabetes Foundation 2000, 2001 Reviewer, Diabetes Endocrinology Research Center Pilot Program, Univ. Wash. 1999 JDFI: Special Grant Site Visit Member, Seattle, WA 1999 JDFI: Special Grant Site Visit Member, Harvard Medical School 1997/03 Ad hoc review: American Diabetes Association grant review 1996/10 Ad hoc review: NIH/NIDDK Surgery, Anesthesia, Trauma Study Section, Ad Hoc reviewer (Oct 17-19/96) 1996/06 Ad hoc review: NIH/NIAID Special Emphasis Panel (June 27/96) 1996/03 Medical Research Council of Canada/JDFI Committee, Montreal, Canada (March 25-26/96) 1995 NIH: GCRC site visit member, Northwestern University 1995 NIH: NIAID Special Emphasis Panel; RFA NIH-NIAID-95-05 1995/02 NIH: NIDDK Surgery, Anesthesia, Trauma Study Section, Ad Hoc reviewer (Feb 22-24/95) 1994 NIH: NIDDK Surgery and Bioengineering Study Section, Ad Hoc reviewer 1994 NIH: NIDDK Surgery, Anesthesia, Trauma Study Section, Ad Hoc reviewer

PUBLICATIONS

Peer-Reviewed Publications 1. Clark W, Gill R. Effect of membrane lipid composition on immune cell function. In: Twelfth International Leukocyte Culture Conference. M. Quastel, ed., Academic Press, New York, pp. 613-619, 1979. 2. Mandel G, Shimizu S, Gill R, Clark W. Alteration of the fatty acid composition of membrane phospholipids in mouse lymphoid cells. J. Immunol. 120:1631-1636, 1978. 3. Gill R, Clark W. Membrane structure-function relationships in cell-mediated cytolysis. I. Effect of exogenously incorporated fatty acids on effector cell function in cell-mediated cytolysis. J. Immunol. 125:689-695, 1980. 4. Bialick R, Gill R, Berke G, Clark WR. Modulation of cell-mediated cytotoxicity function after alteration of fatty acid composition in vitro. J. Immunol. 132:81-87, 1984. 5. Lafferty KJ, Gill R, Babcock S. Tolerance induction in adult animals: the ciclosporin anomaly. Prog. Allergy 38:247-257, 1986. 6. Lafferty KJ, Babcock SK, Gill RG. Prevention of rejection by treatment of the graft: an overview. In: Transplantation: progress and prospect (Meryman H, ed.), Alan R. Liss, Inc. New York, pp. 87-117, 1986. 7. Lafferty KJ, Gill R, Babcock S, Simeonovic C. Activation and expression of allograft immunity. Prog. Transplantation 3:55-84, 1986. 8. Babcock SK, Gill RG, Bellgrau D, Lafferty KJ. Studies on the two signal model for T cell activation in vivo. Transplant Proc. 19:303-306, 1986 9. Lafferty KJ, Gill RG, Babcock SK, Wang Y. Active and passive antigen presentation: its role in the induction of tissue immunity and allograft tolerance. Prog. Immunol. 6:1040- 1054, 1986. 10. Lafferty KJ, Prowse SJ, Babcock SK, Gill RG. The allograft response. Surg. Clinics of N. Amer. 66:1231-1253, 1986. 11. Gill RG, Babcock SK, Lafferty KJ. A quantitative analysis of antigen-triggered lymphokine production by activated T cells. J. Immunol. 138:1130-1136, 1987. 12. Wang Y, Hao L, Gill RG, Lafferty KJ. Autoimmune diabetes in the NOD mouse is L3T4 T- lymphocyte dependent. Diabetes 36:535-538. 1987. 13. Haug CE, Gill RG, Babcock SK, Lafferty KJ, Bellgrau D, Weil R, III. Cyclosporine-induced tolerance requires antigens capable of initiating an immune response. J. Immunol. 139:2947-2949, 1987. 14. Hao L, Wang Y, Gill RG, Lafferty KJ. Role of the L3T4+ T cell in allograft rejection. J. Immunol. 139:4022-4026, 1987. 15. Hao L, Wang Y, Gill RG, Lafferty KJ. CD4 T cells and allograft rejection. Transplant. Proc. 20:56-60, 1988 16. Gill R, Lafferty KJ. A novel form of T-T collaboration requiring the active participation of the antigen presenting cell. Ann. N.Y. Acad. Sci. 532:421-423, 1988. 17. Gill RG, Wang Y, Lafferty KJ. Spontaneous tolerance induction in adult animals transplanted with allogeneic islets. Transplant. Proc. 20:61-63, 1988.

18. Gill RG, Lafferty KJ. Regulation of lymphokine release involving a novel form of T-T collaboration. Transplant. Proc. 21:2700-2702, 1989. 19. Gill RG, Lafferty KJ. Role of islet transplantation in the treatment of insulin-dependent diabetes mellitus. Imm. Allergy Clin. No. Amer. 9:165-186, 1989. 20. Lafferty KJ, Gill RG. Current controversies and new horizons: is there a clinical future for the modulation of donor organ immunogenicity? In: Organ transplantation: current clinical and immunological concepts (Brent L and Sells RA, ed.), Bailliere Tindall, Ltd. London pp. 167-176, 1989. 21. Gill RG, Rosenberg AS, Lafferty KJ, Singer A. Characterization of primary T cell subsets mediating rejection of pancreatic islet grafts. J. Immunol. 143:2176-2178, 1989. 22. Gill RG, Lafferty KJ. A quantitative analysis of lymphokine release from activated T cells: evidence for a novel form of T-T collaboration in vitro. J. Immunol. 143:4009-4014, 1989. 23. Gill RG, Lafferty KJ. Antigen, cytokines, and the regulation of the allograft response. Prog. Immunol. 7:1163-1170, 1989. 24. Hao L, Wang Y, Gill RG, LaRosa FG, Talmage DW, Lafferty KJ. Role of γ-interferon in islet allograft rejection: class I MHC antigen induction. Transplant. Proc. 21:2697-2699, 1989. 25. Gill RG, Lafferty KJ. The nature of T-T collaboration in the rejection of class I MHC- disparate pancreatic islet allografts. J. Cell. Biochem (Supp. 13A):1318, 1989. 26. Hao L, Wang Y, Gill RG, LaRosa F, Talmage D, Lafferty KJ. Role of lymphokine in islet allograft rejection. Transplantation 9:609-614, 1990. 27. Gill RG. Role of passenger leukocytes in islet allograft immunity. Clinical Transplant. 4:176-180, 1990. 28. Wang Y, Pontesilli O, Gill RG, LaRosa FG, Talmage DW, Lafferty KJ. The role of CD4+ and CD8+ T cells in the destruction of islet grafts by spontaneously diabetic mice. Proc. Natl. Acad. Sci. USA 88:527-531, 1991. 29. Gill RG. Transforming growth factor beta prevents islet allograft rejection. Transplant. Proc. 23:747-748, 1991. 30. Coulombe M, Hao L, Calcinaro F, Gill RG, Eugui EM, Allison AC, Lafferty KJ. Tolerance induction in adult animals: comparison of RS-61443 and anti-CD4 treatment. Transplant. Proc. 23:(Suppl 2) 31, 1991. 31. Hao L, Calcinaro F, Gill RG, Eugui EM, Allison AC, Lafferty KJ. Facilitation of specific tolerance induction in adult mice by RS-61443. Transplantation 53:590-595, 1992. 32. Gill RG. The role of direct and indirect antigen presentation in the response to islet xenografts. Transplant. Proc. 24:642-643, 1992. 33. Gill RG, Coulombe M. Rejection of pancreatic islet xenografts does not require CD8+ T lymphocytes. Transplant. Proc. 24:2877-2878, 1992. 34. Gill RG, Haskins K. Molecular mechanisms underlying diabetes and other autoimmune disease. Immunol. Today 14:49-51, 1993. 35. Gill RG, Hao L, Lafferty KJ. Antigen presentation and alloimmunity. In: Immunology of Liver Transplantation (Neuberger J and Adams D, ed.), Edward Arnold, pp. 115-126, 1993. 36. Wolf L, Gill RG. Xenoreactive T-cell lines initiate pancreatic islet graft destruction in vivo. Transplant. Proc. 25:440-441, 1993.

37. Lafferty KJ, Gill RG. The maintenance of self tolerance. Immunol. Cell Bio. 71:209-214, 1993. 38. Gill RG. Pancreatic islet xenotransplantation. Autoimmunity 15 (Suppl 1):18-20, 1993. 39. Gill RG. T-cell-T-cell collaboration in allograft responses. Curr. Opinion Immunol. 5:782-787, 1993. 40. Wegmann DR, Shehadeh N, Lafferty KJ, Norbury-Glaser N, Gill RG, Daniel D. Establishment of islet-specific T-cell lines and clones from islet isografts placed in spontaneously diabetic NOD mice. J. Autoimmunity 6:517-527, 1993. 41. Shehadeh NN, Gill RG, Lafferty KJ. Mechanism of self-tolerance to endocrine tissue. Springer Semin. Immunopathol. 14:203-220, 1993. 42. Coulombe M, Gill RG. Tolerance induction to cultured islet allografts: I. characterization of the tolerant state. Transplantation 57:1195-1200, 1994. 43. Coulombe M, Gill RG. Tolerance induction to cultured islet allografts: II. status of antidonor reactivity in tolerant animals. Transplantation 57:1201-1207, 1994. 44. Leiter EH, Gill RG. Prevention of autoimmune diabetes in the BB rat by intrathymic islet transplantation at birth. J. Endocrin. Invest. 17:595-599, 1994. 45. Wegmann DR, Gill RG, Norbury-Glaser M, Schloot N, Daniel D. Analysis of the spontaneous T cell response to insulin in NOD mice. J. Autoimmunity 7:833-843, 1994. 46. Coulombe M, Lafferty KJ, Gill RG. Nature of tolerance induction to peripheral (extrathymic) islet allografts. Transplant. Proc. 26:720-721, 1994. 47. Gill RG, Coulombe M. Islet xenografting in autoimmune diabetes. Transplant. Proc. 26:1140-1141, 1994. 48. Gill RG, Wolf L, Daniel D, Coulombe M. CD4+ T cells are necessary and sufficient for islet xenograft rejection. Transplant. Proc 26:1203, 1994. 49. Gill RG. 1994. Pancreatic islet transplantation. In: Molecular Biology of Diabetes, Part I (Draznin B and LeRoith D, ed.), Humana Press Inc, Totowa, New Jersey pp 49-67, 1994. 50. Daniel D, Gill RG, Schloot N, Wegmann D. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur. J. Immunol. 25:1056-1062, 1995. 51. Gill RG, Eisenbarth G. Juvenile diabetes foundation International workshop summary: Antigen specific therapies for the prevention of type I diabetes mellitus. Diabetologia 38:A14-A17, 1995. 52. Gill RG, Wolf L. Immunobiology of cellular transplantation. Cell Transplantation 4:361- 370, 1995. 53. Stegall MD, Ostrowska A, Haynes J, Karrer F, Kam I, Gill RG. Prolongation of islet allograft survival with an antibody to vascular cell adhesion molecule 1. Surgery 118:366- 370, 1995. 54. Wolf LA, Coulombe M, Gill RG. Donor antigen presenting cell independent rejection of islet xenografts. Transplantation 60:1164-1170, 1995. 55. Karrer FM, Gill R, Ostrowska A, Bolwerk A, Reitz B, Stegall M, Schroter G, Kam I, Lafferty KJ. Purified hepatic parenchymal cells are non-immunogenic in vitro. Transplant. Proc. 27:625-627, 1995.

56. Coulombe M, Gill RG. T lymphocyte indifference to extrathymic islet allografts. J. Immunol. 156:1998-2003, 1996. 57. Gill RG. Immunobiology of islet transplantation. In: Type I Diabetes (Eisenbarth G and Lafferty KJ, ed.), Oxford Univ. Press pp. 118-133, 1996. 58. Gill RG, Coulombe M, Lafferty KJ. Pancreatic islet allograft immunity and tolerance: the two-signal hypothesis revisited. Immunol. Rev. 149:75-96, 1996. 59. Stegall MD, Lafferty KJ, Kam I, Gill RG. Evidence of autoimmunity in human allogeneic islet transplantation. Transplantation 61:1272-1274, 1996. 60. Stegall MD, Loberman Z, Ostrowska A, Coulombe M, Gill RG. Autoimmune destruction of islet grafts in the NOD mouse is resistant to 15-deoxyspergualin but sensitive to anti-CD4 antibody. J. Surg. Res. 64:156-60, 1996. 61. Coulombe M, Yang H, Guerder S, Flavell R, Lafferty K, Gill RG. Tissue immunogenicity: the role of MHC antigen and the lymphocyte costimulator B7-1. J. Immunol. 157:4790- 4795, 1996. 62. Coulombe M, Yang H, Gill RG. Adoptive transfer of CD4 T cell dependent allograft tolerance. Transplant. Proc. 29:1166-1167, 1997. 63. Crawford M, Daniel D, Wegmann D, Yang H, Gill RG. Autoimmune islet damage mediated by insulin-specific T cells. Transplant. Proc. 29:758-759, 1997. 64. Karrer FM, Bilir G, Gill RG, Ostrowska A, Stegall M, Wachs M, Kam I. Cryopreserved hepatocytes are poor stimulators of in vitro cytotoxicity. Transplant. Proc. 29:1111-1112, 1997. 65. Gill RG. The role of deletion versus regulation in the maintenance of self-tolerance. Diab. Met. Rev. 13:309-314, 1998. 66. Gill RG. Direct and indirect pathways of immunity to pancreatic islet transplants. Transplant. Rev. 12:85-95, 1998. 67. Coulombe M, Yang H, Wolf LA, Gill RG. Tolerance to APC-depleted islet allografts is CD4 T cell dependent. J. Immunol. 162:2503-2510, 1999. 68. Gill RG. Antigen presentation pathways for immunity to islet transplants. Relevance to immunoisolation. Annals N. Y. Acad. Sci. 875:255-260, 1999. 69. Kelemen K, Crawford ML, Gill RG, Hutton JC, Wegmann D. Cellular immune response to Phogrin in the NOD mouse: cloned T cells cause destruction of islet transplants. Diabetes. 48:1529-1534, 1999. 70. Hunkeler D, Sun AM, Korbutt GS, Rajotte RV, Gill RG, Calafiore R, Morel P. Bioartificial organs and acceptable risk. Nature Biotechnol. 17:1045, 1999. 71. Pietra B, Rizeq M, Bolwerk A, Gill RG. CD4 T cells acutely reject cardiac allografts via direct donor recognition. Transplant. Proc. 31:91, 1999. 72. Stegall MD, Elices M, Pietra W, Shepard G, Gup C, Gill RG. Different roles for α4- integrin/VCAM-1 and α4/fibronectin interactions in allograft rejection. Transplant. Proc. 31:786, 1999. 73. Stegall MD, Elices M, Shepard G, Gup C, Ninova D, Ferguson D, Gill RG. The 2C T-cell transgenic mouse: an in vivo model of allospecific cytotoxic T-cell activation and homing. Transplant. Proc. 31:779, 1999.

74. Kawasaki E, Gill RG, Eisenbarth GS. Type I diabetes mellitus. In: Endocrine and Organ Specific Autoimmunity (Eisenbarth GS, ed.), RG Landes Co. pp.149-182, 1999. 75. Nicolls MR, Coulombe M, Yang H, Bolwerk A, Gill RG. Anti-LFA-1 therapy induces long- term islet allograft acceptance in the absence of IFNγ or IL-4. J. Immunol. 164:3627-3634, 2000. 76. Diamond AS, Gill RG. An essential contribution by interferon-gamma to CD8+ T cell- mediated rejection of pancreatic islet allografts. J. Immunol. 165:247-255, 2000. 77. Pietra BA, Wiseman A, Bolwerk A, Rizeq M, Gill RG. CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC Class II. J. Clin. Invest. 106:1003- 1010, 2000. 78. Stegall MD, Dean PG, Ninova D, Cohen AJ, Shepard GM, Gup C, Gill RG. α4 integrin in islet allograft rejection. Transplantation 71:1549-1555, 2001. 79. Gill RG. Cellular immune responses to xenografts. In: Xenotransplantation (Platt J, ed.), ASM Press, Washington, D.C. pp. 99-115, 2001. 80. Pietra BA, Gill RG. Immunobiology of cardiac allograft and xenograft transplantation. Semin. Thorac. Cardiovasc. Surg. Pediatr. Surg. Annu. 4:123-157, 2001. 81. Nicolls MR, Coulombe M, Gill RG. The basis of immunogenicity of endocrine allografts. Crit. Rev. Immunol. 21:87-101, 2001. 82. Gill RG. Use of small animal models for screening immunoisolation approaches to cellular transplantation. Ann. N.Y Acad. Sci. 944:35-46, 2001. 83. Wiseman AC, Pietra BA, Kelly BP, Rayat GR, Rizeq M, Gill RG. Donor IFN-γ receptors are critical for acute CD4+ T cell-mediated cardiac allograft rejection. J. Immunol. 167:5457-5463, 2001. 84. Nicolls MR, Coulombe M, Diamond AS, Beilke J, Gill RG. Interferon-γ is not a universal requirement for islet allograft Survival. Transplantation 74:472-477, 2002. 85. Nicolls MR, Coulombe M, Beilke J, Gelhaus HC, Gill RG. CD4 dependent generation of dominant transplantation tolerance induced by simultaneous perturbation of CD154 and LFA- 1 pathways. J. Immunol. 169:4831-4839, 2002. 86. Coulombe M, Gill RG. Immunobiology of endocrine gland transplantation. In: Immunologically Mediated Endocrine Disease (Gill RG, Harmon J, Maclaren N, ed.), Lippincott-Raven, Publishers pp. 83-102, 2002 87. Gill RG. Animal models of pancreatic islet xenotransplantation. Curr. Opin. Organ Transplantation 8:64-69, 2003. 88. Nicolls MR, D’Antonio JM, Hutton JC, Gill RG, Czwornog JL, Duncan MW. Proteomics as a tool for discovery: Proteins implicated in Alzheimer’s disease are highly expressed in normal pancreatic islets. J. Proteome Res. 2:199-205, 2003. 89. Rayat GR, Johnson ZA, Beilke JN, Korbutt GS, Rajotte RV, Gill RG. The degree of phylogenetic disparity of islet grafts dictates the reliance of indirect CD4 T cell antigen recognition for rejection. Diabetes 52:1433-1440, 2003. 90. Rayat GR, Gill RG. Pancreatic islet xenotransplantation: barriers and prospects. Curr. Diab. Rep. 3:336-343, 2003. 91. Moriyama H, Abiru N, Paronen J, Sikora K, Liu E, Miao D, Devendra D, Beilke J, Gianani R, Gill RG, Eisenbarth GS. Evidence for a primary islet autoantigen (preproinsulin 1) for

insulitis and diabetes in the NOD mouse. Proc. Natl. Acad. Sci. USA 100:10376-10381, 2003. 92. Hunkeler D, Rajotte R, Grey D, Morel P, Skjak-Break G, Korbutt G, Gill R, Oberholzer J. Bioartificial organ grafts: a view at the beginning of the third millennium. Artif. Cell Blood Substit. Immobil. Biotechnol. 31:365-382, 2003. 93. Johnson Z, Beilke J, Pietra B, Kelly B, Gill RG. Distinct requirements for host CD80/CD86 costimulatory molecules in cardiac versus islet rejection. Transplant. Proc. 36:1171-1172, 2004. 94. Beilke J, Johnson Z, Kuhl N, Gill RG. A major role for host MHC class I antigen presentation for promoting islet allograft survival. Transplant. Proc. 36:1173-1174, 2004. 95. Wiseman AC, Gill RG. Current status of clinical islet transplantation: advances and obstacles. Curr. Opin. Endocrinol. Diabetes 11:98-103, 2004. 96. Grazia TJ, Pietra BA, Johnson ZA, Kelly BP, Plenter RJ, Gill RG. A two-step model of acute CD4 T-cell mediated cardiac allograft rejection J. Immunol. 172:4751-7458, 2004. 97. Coulombe M, Gill RG. Tolerance induction to pancreatic islet allografts. Curr. Opin. Organ Transplant 9:258-263, 2004. 98. Homann D, Gill RG. To help and help not. Nat. Immunol. 5:878-880, 2004. 99. Coulombe M, Gill RG. The immunobiology of pancreatic islet transplantation. Adv. Exp. Med. Biol. 552:154-169, 2004. 100. Rayat GR, Gill RG. Indefinite survival of neonatal porcine islet xenografts by simultaneous targeting of LFA-1 and CD154 or CD45RB. Diabetes 54:443-451, 2005. 101. Murakawa T, Kerklo MM, Zamora MR, Wei Y, Gill RG, Henson PM, Grover FL, Nicolls MR. Simultaneous LFA-1 and CD40 ligand antagonism prevents airway remodeling in orthotopic airway transplantation: implications for the role of respiratory epithelium as a modulator of fibrosis. J. Immunol. 174:3869-3879, 2005. 102. Wiseman AC, Gill RG. The continuing progress and challenges of clinical islet transplantation. Curr. Opin. Endo. Diab. 12:291-297, 2005. 103. Kupfer TM, Crawford ML, Pham K, Gill RG. MHC-mismatched islet allografts are vulnerable to autoimmune injury. J. Immunol. 175:2309-2316, 2005. 104. Grazia TJ, Gill RG, Gelhaus HC, Doan AN, Sleater ML, Pietra BA. Perturbation of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 results in differential outcomes in cardiac vs islet allograft survival. J. Heart Lung Transplant 24:1410-1414, 2005. 105. Faubel S, Ljubanovic D, Poole B, Dursun B, He Z, Cushing S, Somerset H, Gill RG, Edelstein CL. Peripheral CD4 T cell depletion is not sufficient to prevent ischemic acute renal failure. Transplantation 80:643-649, 2005. 106. Beilke JN, Kuhl NR, Van Kaer L, Gill RG. NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nat. Med. 11:1059-1065, 2005. 107. Nicolls MR, Gill RG. Mini review: LFA-1 (CD11a) as a therapeutic target. Am. J. Transplant. 6:27-36, 2006. 108. Gianani R, Putnam A, Still T, Yu L, Miao D, Gill RG, Beilke J, Supon P, Valentine A, Iveson A, Dunn S, Eisenbarth GS, Hutton J, Gottlieb P, Wiseman A. Initial results of screening of non-diabetic organ donors for expression of islet autoantibodies. J. Clin. Endocrin. Metab. 91:1855-1861, 2006.

109. Mack CL, Tucker RM, Fontenot AP, Sokol RJ, Gill RG. Cellular and humoral autoimmunity directed at bile duct epithelia in murine biliary atresia. Hepatology 44:1231- 1239, 2006. 110. Crossno JT Jr, Majka SM, Grazia T, Gill RG, Klemm DJ. Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells. J. Clin. Invest. 116:3220-3228, 2006. 111. Beilke JN, Gill RG. Frontiers in nephrology: the varied faces of natural killer cells in transplantation contributions to both allograft immunity and tolerance. J. Am. Soc. Nephrol. 18:2262-2267, 2007. 112. Sleater M, Diamond AS, Gill RG. Islet allograft rejection by contact-dependent CD8+ T cells: perforin and FasL play alternate but obligatory roles. Am J. Transplant. 7:1927-1933, 2007. 113. Nakayama M, Beilke JN, Jasinski JM, Kobayashi M, Miao D, Li M, Coulombe MG, Liu E, Elliott JF, Gill RG, Eisenbarth GS. Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity. J. Clin. Invest. 117:1836-1843, 2007. 114. Sarkar SA, Gunter J, Bouchard R, Reusch JE, Wiseman A, Gill RG, Hutton JC, Pugazhenthi S. Dominant negative mutant forms of the cAMP response element binding protein induce apoptosis and decrease the anti-apoptotic action of growth factors in human islets. Diabetologia 50:1649-1659, 2007. 115. Grazia TJ, Plenter RJ, Doan AN, Kelly BP, Weber SM, Kurche JS, Cushing SO, Gill RG, Pietra BA. Spontaneous allograft tolerance in B7-deficient mice independent of preexisting endogenous CD4+ CD25+ regulatory T-cells. Transplantation 83:1449-1458, 2007. 116. Tucker RM, Hendrickson RJ, Mukaida N, Gill RG, Mack CL. Progressive biliary destruction is independent of a functional tumor necrosis factor-alpha pathway in a rhesus rotavirus-induced murine model of biliary atresia. Viral Immunol. 20:34-43, 2007. 117. Sarkar SA, Wong R, Hackl SI, Moua O, Gill RG, Wiseman A, Davidson HW, Hutton JC. Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets. Diabetes 56:72-79, 2007. 118. Arefanian H, Tredget EB, Rajotte RV, Korbutt GS, Gill RG, Rayat GR. Combination of anti-CD4 with anti-LFA-1 and anti-CD154 monoclonal antibodies promotes long-term survival and function of neonatal porcine islet xenografts in spontaneously diabetic NOD mice. Cell Transplantation 16:787-798, 2007. 119. Tredget EB, Arefanian H, Gill RG, Rajotte RV, Rayat GR. Monotherapy with anti-LFA-1 monoclonal antibody promotes long-term survival of rat islet xenografts. Cell Transplantation 17:599-608, 2008. 120. Kupfer T, Beilke JN, Pham K, Buhrman J, Gill RG. ‘Indirect’ acute islet allograft destruction in NOD mice is independent of donor MHC and requires host B lymphocytes. Transplant. Proc. 40:462-463, 2008. 121. Ramirez-Victorino F, Beilke JN, Gill RG. Both innate and adaptive MHC class I-dependent immunity impair long-term islet xenograft survival. Transplant. Proc. 40:557-558, 2008. 122. Grazia, TJ, Plenter RJ, Weber SM, Lepper HM, Victorino F, Pietra BA, Gill RG. Acute cardiac rejection requires directly cytotoxic CD4 T cells: parallel requirements for Fas and perforin. Transplantation 89:33-39, 2010

123. Arefanian, H, Tredget EB, Rajotte RV, Gill RG, Korbutt GS, Rayat GR. Short-term administrations of a combination of anti-LFA-1 and anti-CD154 monoclonal antibodies induce tolerance to neonatal islet xenografts in mice. Diabetes 59:958-966, 2010 124. Sklavos, MM, Bertera S, Tse HM, Bottino R, He J, Beilke JN, Coulombe MG, Gill RG, Crapo JD, Trucco M, Piganelli JD. Redox modulation protects islets from transplant-related injury. Diabetes 59:1730-1738, 2010 125. Gill RG. Just how stable is allograft tolerance? Am. J. Transplant. 10:1499-1500, 2010 126. Gill RG. NK cells: Elusive participants in transplantation immunity and tolerance. Curr. Opin. Immunol. 22:649-654, 2010 127. Grazia, TJ, Plenter RJ, Lepper HM, Victorino F, Miyamoto SD, Crossno JT, Pietra BA, Gill RG, Zamora MR. Prolongation of cardiac allograft survival by a novel population of autologous CD117+ bone marrow-derived progenitor cells. Am. J. Transplant. 11:34-44, 2011 Book Editor

1. Immunologically Mediated Endocrine Diseases. Gill, RG, J Harmon, N Macleren, Eds. Lippincott-Raven Publishers, 2002

Scientific Abstracts (since 1990 only)

1. Hao, L, R Calcinaro, R Gill, K Lafferty, A Allison, E Eugui. The immunosuppressive drug RS-61443 induces donor-specific allograft tolerance. XIII International Congress of the Transplantation Society. San Francisco, California. August 19-24, 1990. 2. Gill, R. Transforming growth factor β (TGF-β) prevents islet allograft rejection. XIII International Congress of the Transplantation Society. San Francisco, California. August 19- 24, 1990. 3. Hao, L, M Coulombe, F Calcinaro, RG Gill, KJ Lafferty. Graft acceptance need not indicate tolerance induction. Symposium on Tolerance Induction. Breckenridge, Colorado. January 13-16, 1991. 4. Wolf, L, RG Gill. Xenoreactive T cell lines initiate islet graft destruction in vivo. XIVth International Congress of the Transplantation Society. Paris, France. August 16-21, 1992. 5. Gill, RG. The role of T lymphocyte subsets in islet xenograft rejection. XIVth International Congress of the Transplantation Society. Paris, France. August 16-21, 1992. 6. Coulombe, M, KJ Lafferty, RG Gill. Tolerance induction to non-immunogenic pancreatic islet allografts. XIVth International Congress of the Transplantation Society. Paris, France. August 16-21, 1992. 7. LaRosa, FG, MJ Duggan, R Gill, M Coulombe, K Haskins, K Gosselin. Role of MHC antigen expression on NOD pancreatic-islet cells in the development of type-1 diabetes. FASEB Journal. 6:A1694, 1992 8. Gill, RG, M Coulombe. Tolerance induction to peripheral (extrathymic) islet allografts. Third Basic Sciences Symposium of The Transplantation Society. Big Sky, Montana. September 8-11, 1993. 9. Gill, RG, M Coulombe. Lack of peripheral (extrathymic) tolerance induction to pancreatic islet allografts. American Association of Immunologists (AAI) Meeting. Denver, Colorado, 1993 10. Coulombe, M., RG Gill. T cell indifference to extrathymic alloantigens. XVth World Congress of the Transplantation Society. Kyoto, Japan. August 28-September 2, 1994. 11. Wolf. L, D Daniel, M Coulombe, RG Gill. CD4+ T cells are sufficient to trigger islet xenograft rejection. XVth World Congress of the Transplantation Society. Kyoto, Japan. August 28-September 2, 1994. 12. Gill, RG, M Coulombe. Islet xenograft survival in autoimmune diabetes. XVth World Congress of the Transplantation Society. Kyoto, Japan. August 28-September 2, 1994. 13. Scholl, M, D Daniel, D Wegmann, H Yang, RG Gill. Destruction of xenogeneic islet grafts triggered by NOD-derived, insulin-specific T cells in vivo. 55th Meeting & Scientific Sessions of the American Diabetes Association. Atlanta, Georgia. June 10-13, 1995 Diabetes 44 (Suppl. 1):10A (abstract), 1995 14. Scholl, M, D Daniel, D Wegmann, H Yang, RG Gill. Xenogeneic islet cell destruction by insulin-specific T lymphocytes. 5th International Congress on Pancreas and Islet Transplantation. Miami Beach, Florida. June 18-22, 1995. 15. Yang, H, M Coulombe, R Flavell, K Lafferty, RG Gill. The basis of tissue immunogenicity. 5th International Congress on Pancreas and Islet Transplantation. Miami Beach, Florida. June 18-22, 1995.

16. Coulombe, M, H Yang, S Guerder, R Flavell, K Lafferty, R Gill. Tissue immunogenicity: the role of antigen and costimulation. 4th Basic Sciences Symposium of the Transplantation Society. Noordwijkerhout, The Netherlands. September 17-20, 1995. 17. Scholl, M, D Daniel, D Wegmann, H Yang, RG Gill. Destruction of xenogeneic islet grafts triggered by NOD-derived, insulin-specific T cells in vivo. The Third International Congress for Xenotransplantation. Boston, Massachusetts. September 27-October 1, 1995. 18. Coulombe M, H Yang, S Guerder, RA Flavell, KJ Lafferty, RG Gill. The basis of tissue immunogenicity. American Association of Immunologists Meeting. New Orleans, LA. June 1-6, 1996. 19. Scholl M, H Yang, D Daniel, D Wegmann, RG Gill. Autoimmune islet damage triggered by CD4+ insulin specific T cells. American Association of Immunologists Meeting. New Orleans, LA. June 1-6, 1996. 20. Diamond, A, H Yang, A Bolwerk, RG Gill. Cytokine regulation of allograft destructive CD8 T cells. XVIth International Congress of the Transplantation Society. Barcelona, Spain. August 25-30, 1996. 21. Scholl, M, D Daniel, D Wegmann, H Yang, RG Gill. Autoimmune islet damage mediated by insulin-specific T cells. XVIth International Congress of the Transplantation Society. Barcelona, Spain. August 25-30, 1996. 22. Coulombe, M, H Yang, RG Gill. Adoptive transfer of CD4 T-cell dependent allograft tolerance. XVIth International Congress of the Transplantation Society. Barcelona, Spain. August 25-30, 1996. 23. Karrer, FM, B Bilir, RG Gill, A Ostrowska, M Stegall, M Wachs, I Kam. Cryopreserved hepatocytes are poor stimulators of in vitro cytotoxicity. XVIth International Congress of the Transplantation Society. Barcelona, Spain. August 25-30, 1996. 24. Stegall, M, M Elices, G Shepard, J Haynes, M Wachs, I Kam, R Gill. Prevention of islet allograft rejection by inhibiting lymphocyte extracellular matrix interactions. 57th Annual Meeting and Scientific Sessions, American Diabetes Association. Diabetes. 46(S1):63A, 1997. 25. Diamond, A, H Yang, A Bolwerk, RG Gill. Mechanism of CD8-dependent rejection of pancreatic islet allografts. 16th Annual Meeting of the American Society of Transplant Physicians. Chicago, IL. May 10-17, 1997. 26. Pietra, BA, L Wolf, M Coulombe, A Bolwerk, H Yang, RG Gill. CD4 T cells are sufficient for cardiac but not pancreatic islet allograft rejection. 16th Annual Meeting of the American Society of Transplant Physicians. Chicago, IL. May 10-17, 1997. 27. Pietra, BA, RG Gill. CD4 T cells are sufficient for acute cardiac allograft and xenograft rejection. 16th Annual Meeting of the American Society of Transplant Physicians. Chicago, IL. May 10-17, 1997. 28. Stegall, MD, C Gup, G Shepard, RG Gill. The role of a4 integrin/fibronectin interactions in allospecific cytotoxic T cell activation and homing--initial studies in the 2C T-cell receptor transgenic. 17th Annual Meeting of the American Society of Transplant Physicians. Chicago, IL. May 10-13, 1998. 29. Coulombe, M., H Yang, M Nicolls, A Bolwerk, R Araujo, and RG Gill. Transferable allograft tolerance induced by anti-LFA-1 (CD11a) therapy. 17th Annual Meeting of the American Society of Transplant Physicians. Chicago, IL. May 10-13, 1998.

30. Yang, H, A Bolwerk, D Walborn, and RG Gill. CD4-mediated islet xenograft rejection requires indirect antigen recognition. 17th Annual Meeting of the American Society of Transplant Physicians. Chicago, IL. May 10-13, 1998. 31. Pietra, BA, M Rizeq, RG Gill. Chronic cardiac allograft rejection is independent of donor MHC class II antigens. 17th Annual Meeting of the American Society of Transplant Physicians. Chicago, IL. May 10-13, 1998. 32. Pietra, BA, M Rizeq, RG Gill. Acute CD4-mediated cardiac allograft rejection requires donor class II MHC molecules. 17th Annual Meeting of the American Society of Transplant Physicians. Chicago, IL. May 10-13, 1998. 33. Stegall, MD, G Shepard, C Gup, RG Gill. Long-term protection against adoptive transfer of IDDM in the NOD mouse by blocking multiple integrins. 58th Scientific Session of the American Diabetes Association. June 13-16, 1998. Diabetes 47(suppl 1): A199, 1998 34. Pietra, RG, M Rizeq, RG Gill. CD4 T cells reject cardiac allografts via direct donor recognition. XVII World Congress of the Transplantation Society. Montreal, Canada, July 12-17, 1998. 35. Stegall, MD, W Pietra, G Hepard, C Gup, RG Gill. Different roles for α4-integrin/VCAM-1 and α4/Fibronectin interactions in allograft rejection. XVII World Congress of the Transplantation Society. Montreal, Canada, July 12-17, 1998. 36. Stegall, MD, G Shepard, C Gup, RG Gill. The 2C T-cell transgenic mouse: an in vivo model of allospecific cytotoxic T cell activation and homing. XVII World Congress of the Transplantation Society. Montreal, Canada, July 12-17, 1998. 37. Yang, H, A Bolwerk, D Walborn, RG Gill. Islet xenograft rejection requires indirect antigen recognition. XVII World Congress of the Transplantation Society. Montreal, Canada, July 12-17, 1998. 38. Diamond, A, RG Gill. Biphasic Roles for IFNγ in Islet Allograft Immunity and Tolerance. Keystone Symposium, Molecular and Cellular Biology of Transplantation. Lake Tahoe, Nevada, March 21-26, 1999 39. Gill, RG, A Bolwerk, H Yang. Indefinite Islet Xenograft Survival Induced by Anti-LFA-1 (CD11a) Therapy. Keystone Symposium, Molecular and Cellular Biology of Transplantation. Lake Tahoe, Nevada, March 21-26, 1999 40. Pietra, BA, M Rizeq, RG Gill. CD4 T cells can provide help via the indirect pathway to reject MHC class II-/- hearts. 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999. Transplantation 67:S7, 1999 41. Wiseman, AC, BA Pietra, MA Rizeq, RG Gill. The CD4+ effector T cell requires IFN-γ to mediate acute cardiac allograft rejection. 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999 (AST young investigator award). Transplantation 67:S22, 1999 42. Diamond, A, RG Gill. Biphasic roles for IFNγ in islet allograft immunity and tolerance. 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999. Transplantation 67:S23, 1999 43. Nicolls, MR, M Coulombe, RG Gill. IFNγ and IL-4 are not required for anti-LFA-1-induced islet allograft prolongation. 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999 (AST young investigator award). Transplantation 67:S35, 1999

44. Crawford, M, K Haskins, RG Gill. Fas (CD95)-independent islet allograft destruction mediated by CD4+ islet-specific T cells. 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999. Transplantation 67:S36, 1999 45. Kalayanamit, T, A Bolwerk-Varra, A Valentine, RG Gill. Islet xenograft prolongation mediated by anti-CD45RB monotherapy. 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999. Transplantation 67:S138, 1999 46. Gill, RG, A Bolwerk, H Yang. Indefinite islet xenograft survival induced by anti-LFA-1 (CD11a) therapy. 18th Annual Meeting of the American Society of Transplantation, May 15- 19, 1999 (AST poster of distinction). Transplantation 67:S138, 1999 47. Pietra, BA, RG Gill, A Wiseman, M Rizeq, J Robbins, MM Boucek, DP Nelson. FasL interferes with effector CD4 T cell mediated rejection of cardiac allografts. 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999. Transplantation 67:S206, 1999 48. Nelson, DP, BA Pietra, E Setser, A Akanbi, R Klevitsky, H Osinska, RG Gill, J Robbins. Life in the Fas L(ane): cardiac FasL expression is both pro-inflammatory and immune- protective. Circulation 100 (suppl):284, 1999 49. Gill, RG, J Beilke, and M Coulombe. Contribution to acute islet allograft rejection by CD4- dependent indirect recognition of donor antigens. 1st Joint Meeting of the American Society of Transplantation. May 13-17, 2000. Chicago, IL. 50. Malecki, TM, M Crawford, and RG Gill. Islet allograft destruction by islet-specific CD4 T cells occurs via indirect antigen presentation. 1st Joint Meeting of the American Society of Transplantation. May 13-17, 2000. Chicago, IL. 51. Kalayanamit, T, J Beilke, and RG Gill. Maintenance of islet xenograft prolongation by anti- CD45RB therapy requires CD4 T cells. 1st Joint Meeting of the American Society of Transplantation. May 13-17, 2000. Chicago, IL. 52. Wiseman, AC, BA Pietra, and RG Gill. Graft IFN-γ receptors are necessary for the effector phase of CD4-mediated acute cardiac allograft rejection. 1st Joint Meeting of the American Society of Transplantation. May 13-17, 2000. Chicago, IL. 53. Diamond, AS and RG Gill. Resistance to induction of long-term allograft survival in IFNγ- deficient mice maps to hyperaggressive CD8 T cell subset. 1st Joint Meeting of the American Society of Transplantation. May 13-17, 2000. Chicago, IL. 54. Coulombe M, M Nicolls, J Beilke, A Bolwerk, and RG Gill. Efficacy of allograft tolerance induced by anti-LFA-1 therapy maps to non-MHC genes. 1st Joint Meeting of the American Society of Transplantation. May 13-17, 2000. Chicago, IL. 55. Beilke J, N Kuhl, and RG Gill. Prolongation of islet xenografts by anti-LFA-1 therapy is CD4-T cell dependent. 1st Joint Meeting of the American Society of Transplantation. May 13-17, 2000. Chicago, IL. 56. Rayat, GR, JN Beilke, N Kuhl, A Bolwerk, RG Gill. Resistance to islet xenograft prolongation in NOD mice is independent of autoimmune disease status. The 8th Congress of the International Pancreas and Islet Transplant Association. Act. Chir. Austiraca. 33 (Suppl 174): 51, 2001 57. Rayat, GR, Z Johnson, GS Korbutt, RV Rajotte, RG Gill. CD4+ T cells are sufficient for rejection of neonatal porcine islet xenografts and are dependent on host class II MHC molecules. The 8th Congress of the International Pancreas and Islet Transplant Association. Act. Chir. Austiraca. 33 (Suppl 174): 57, 2001

58. Rayat, GR, JN Beilke, GS Korbutt, RV Rajotte, RG Gill. Hierarchy of dependency on host class II MHC molecules in rejection of pancreatic islet allo- and xenografts. The 8th Congress of the International Pancreas and Islet Transplant Association. Act. Chir. Austiraca. 33 (Suppl 174): 76, 2001 59. Kalayanamit, T, J Beilke, RG Gill. Islet xenograft prolongation by anti-CD45RB therapy requires the continued presence of peripheral CD4 T cells. VI Congress of the International Xenotransplantation Association. Chicago, IL. Xenotransplantation 8(S1): 6, 2001 60. Beilke, J, RG Gill. CD4 T cell dependent survival of islet xenografts induced by anti-LFA-1 (CD11a) therapy. VI Congress of the International Xenotransplantation Association. Chicago, IL. Xenotransplantation 8(S1): 6, 2001 61. Johnson, ZA, RG Gill. Neither NK cells nor host innate immune signaling through the common cytokine receptor gamma chain are required for islet xenograft rejection. . VI Congress of the International Xenotransplantation Association. Chicago, IL. Xenotransplantation 8(S1): 9, 2001 62. Rayat, GR, N Kuhl, RG Gill. Resistance to islet xenograft prolongation in NOD mice is independent of autoimmune syndrome status. VI Congress of the International Xenotransplantation Association. Chicago, IL. Xenotransplantation 8(S1): 2, 2001 63. Rayat, GR, JN Beilke, GS Korbutt, RV Rajotte, RG Gill. A hierarchy in the requirement for host MHC class II molecules in the rejection of pancreatic islet allo- and xenografts. VI Congress of the International Xenotransplantation Association. Chicago, IL. Xenotransplantation 8(S1): 39, 2001 64. Rayat, GR, ZA Johnson, GS Korbutt, RV Rajotte, RG Gill. CD4+ T cells are sufficient for triggering rejection of neonatal porcine islet xenografts and are dependent on host class II MHC molecules. VI Congress of the International Xenotransplantation Association. Chicago, IL. Xenotransplantation 8(S1): 51, 2001 65. Rayat, GR, GS Korbutt, RV Rajotte, RG Gill. Combinational therapies for long-term islet xenograft survival. VI Congress of the International Xenotransplantation Association. Chicago, IL. Xenotransplantation 8(S1): 123, 2001 66. Wiseman, AC, MR Nicolls, AS Diamond, J Beilke, RG Gill. The contribution of IFN-γ to islet allograft survival following anti-CD4 therapy. 10th Anniversary Congress of the Cell Transplant Society. Keystone, CO . Oct, 14-17, 2001. Cell Transplantation 10:527 67. Rayat, GR, GS Korbutt, RV Rajotte, RG Gill. Combination of anti-LFA 1 antibody with anti-CD45RB antibody or anti-CD154 antibody promotes long-term porcine islet xenograft survival. 10th Anniversary Congress of the Cell Transplant Society. Keystone, CO . Oct, 14- 17, 2001. Cell Transplantation 10:526-7 68. Nicolls, MR, M Coulombe, J Beilke, RG Gill. A strategic combination of anti-LFA-1 and anti-CD40L monoclonal antibody therapy induces dominant tolerance in experimental islet transplantation. 10th Anniversary Congress of the Cell Transplant Society. Keystone, CO . Oct, 14-17, 2001. Cell Transplantation 10:523 69. Wiseman, AC, N Kuhl, J Beilke, RG Gill. Anti-CD4-induced islet allograft survival requires donor IFN-g receptors. Am. J. Transplant. 2(Suppl1):153, 2002 70. Gelhaus, HC, MR Nicolls, RG Gill. Deletion of graft specific CD8+ T cells is not necessary for prolonged islet allograft survival. American Transplant Congress 2002. Am. J. Transplant. 2(Suppl1):447, 2002

71. RG Gill, J Beilke N Kuhl. Islet allograft prolongation following costimulation blockade requires an intact host MHC class I presentation pathway. American Transplant Congress 2002. Am. J. Transplant. 2(Suppl1):210, 2002 72. MR Nicolls, M Coulombe, J Beilke, RG Gill. Dominant transplantation tolerance does not require elimination of donor-specific T cells in vivo. American Transplant Congress 2002. Am. J. Transplant. 2(Suppl1):212, 2002. 73. Johnson, ZA, GR Rayat, RG Gill. Profound CD4+ T cell mediated islet xenograft rejection in the absence of NK cell reactivity. American Transplant Congress 2002. Am. J. Transplant. 2(Suppl1); Abstract #520, 2002 74. Malecki, TM, GR Rayat, RG Gill. Autoreactive islet-specific mouse CD4 T cells coordinate the destruction of islet xenografts in vivo. American Transplant Congress 2002. Am. J. Transplant. 2(Suppl 1):466, 2002 75. Rayat GR, GS Korbutt, RV Rajotte, RG Gill. Combinations of monoclonal antibodies promote long-term survival of neonatal porcine islet xenografts. American Transplant Congress. Am. J. Transplant. 2(Suppl1):448, 2002 76. Rayat GR, Korbutt, GS, Rajotte, RG Gill. Combinations of monoclonal antibodies promote long-term survival of neonatal porcine islet xenografts. 2002 Canadian Diabetes Association Meeting. Canad. J. Diabetes 26(3): Abtract#40, 2002 77. Pietra, BA, AZ Johnson, BP Kelly, SO Cushing, RG.Gill. Spontaneous door-specific tolerance to cardiac allografts in the absence of host CD80/86. American Transplant Congress of the ASTS and AST. May 30-June 4, 2003, Washington, D.C. Am. J. Transplant. 3 (S5):194, 2003 78. Gelhaus, HC, RG Gill. Direct impact of tolerizing therapies on graft-destructive CD8 T cells.. American Transplant Congress of the ASTS and AST. May 30-June 4, 2003, Washington, D.C. Am. J. Transplant. 3 (S5):262, 2003. 79. Nicolls, MR, JM DAntonio, MM Kerklo, NE Gomez, JC Hutton, RG Gill, JL Czwornog, MW Duncan. Proteomics as a tool for discovery: proteins implicated in Alzheimer’s disease are highly expressed in normal pancreatic islets. American Transplant Congress of the ASTS and AST. May 30-June 4, 2003, Washington, D.C. Am. J. Transplant. 3 (S5):410, 2003 80. Gelhaus, HC, RG Gill. Paradoxical rescue of donor-specific T cells is associated with active allograft tolerance. American Transplant Congress of the ASTS and AST. May 30-June 4, 2003, Washington, D.C. Am. J. Transplant. 3 (S5):419, 2003 81. Grazia, TJ, RG Gill, J Jensen, JN Jensen, BA Pietra. Contribution of MHC class II expression by donor hematopoietic cells in CD4-mediated cardiac allograft rejection. American Transplant Congress of the ASTS and AST. May 30-June 4, 2003, Washington, D.C. Am. J. Transplant. 3 (S5):539, 2003 82. Beilke, J, Z Johnson, RG Gill. An intact host MHC class I pathway is necessary for long- term islet allograft survival. American Association of Immunologists (AAI) 90th Anniversary Annual Meeting. Denver, CO May 6-10, 2003. FASEB J. 17:C63-64, 2003. 83. Rayat, GR, JN Beilke, RG Gill. Combination of Rapamycin and anti-LFA-1 prevents rejection of rat islet xenografts. 9th Congress of the International Pancreas and Islet Transplant Association (IPITA). July 8-11, 2003. Dublin, Ireland 84. Johnson, Z, J Beilke, B Pietra, B Kelly, RG Gill. Distinct requirements for host CD80/CD86 costimulatory molecules in cardiac versus islet rejection. 9th Congress of the International Pancreas and Islet Transplant Association (IPITA). July 8-11, 2003. Dublin, Ireland

85. Rayat, GR, J Beilke, RG Gill. Genetic resistance of NOD mice to islet allograft versus xenograft prolongation. 9th Congress of the International Pancreas and Islet Transplant Association (IPITA). July 8-11, 2003. Dublin, Ireland 86. Rayat, GR, GS Korbutt, RV Rajotte, RG Gill. Strategic combinations of monoclonal antibodies promote long-term survival of neonatal porcine islet xenografts and is associated with decreased anti-porcine antibody production. 9th Congress of the International Pancreas and Islet Transplant Association (IPITA). July 8-11, 2003. Dublin, Ireland 87. Gill, RG, J Rawson, M Coulombe. B lymphocytes facilitate islet allograft rejection but are not required for tolerance resistance in NOD mice. American Transplant Congress, May 15- 19, 2004, Boston, MA. Am. J. Transplant. 4(Suppl 8):186, 2004. 88. Sleater, M., AS Diamond, A Bolwerk, RG Gill. Perforin and Fas-L (CD95L) form parallel, complementary pathways of CD8 T cell mediated islet allograft rejection. American Transplant Congress; May 15-19, 2004, Boston, MA. Am. J. Transplant. 4(Suppl 8):246, 2004. 89. Johnson, Z, J Beilke, B Pietra, B Kelly, RG Gill. Distinct requirements for host CD80/CD86 costimulatory molecules in cardiac versus islet rejection. American Transplant Congress, May 15-19, 2004, Boston, MA. Am. J. Transplant. 4(Suppl 8):413, 2004. 90. Pietra, BA, RJ Plenter, SO Cushing, A Doan, RG Gill. Long-term cardiac allograft survival after dual therapy with anti-CD40L and anti-LFA-1 antibodies. American Transplant Congress, May 15-19, 2004, Boston, MA. Am. J. Transplant. 4(Suppl 8):430, 2004. 91. Nicolls, MR, MM Kerklo, N Gomez, J Beilke, MW Duncan, RG Gill. Protein biomarkers of metabolic stress in islet transplantation. American Transplant Congress, May 15-19, 2004, Boston, MA. Am. J. Transplant. 4(Suppl 8):469, 2004. 92. Beilke, JN, NR Kuhl, ZA Johnson, RG Gill. An essential requirement for an intact host MHC class I pathway in islet allograft survival. American Transplant Congress, May 15-19, 2004, Boston, MA. Am. J. Transplant. 4(Suppl 8):581, 2004. 93. Grazia, TJ, BA Pietra, ZA Johnson, RJ Plenter, RG Gill. A two step model of acute CD4- mediated cardiac allograft rejection. American Transplant Congress, May 15-19, 2004, Boston, MA. Am. J. Transplant. 4(Suppl 8):584, 2004. 94. Beilke*, JN, NR Kuhl, RG Gill. NK cells play an essential role for anti-CD154 induced islet allograft tolerance. 7th International Congress of the Cell Transplant Society, Nov. 17-20, 2004. Boston, MA (Awarded as one of the top 5 conference abstracts) 95. Sleater, M, AS Diamond, RG Gill. Perforin and FasL/Fas are the predominant effectors of CD8 T cell-mediated islet allograft rejection. 7th International Congress of the Cell Transplant Society, Nov. 17-20, 2004. Boston, MA. 96. Beilke, J, N Kuhl, P Supon, R Gill, A Wiseman. Improved islet cell recovery from donors with a low body mass index: toward making every organ count. 7th International Congress of the Cell Transplant Society, Nov. 17-20, 2004. Boston, MA 87. Gill, RG, K Phan, J Rawson, M Coulombe. B lymphocytes can be dispensable for both the induction and maintenance of islet allograft tolerance. 7th International Congress of the Cell Transplant Society, Nov. 17-20, 2004. Boston, MA 88. Wiseman, AC, J Beilke, N Kuhl, PA Supon, RG Gill. Prolonged warm digestion of human pancreata improves islet cell recovery and transplant rates from young, nonobese donors. 10th

Congress of the International Pancreas and Islet Transplant Association (IPITA). May 6, 2005. Geneva, Switzerland 89. Beilke, JN, NR Kuhl, RG Gill. An essential role for NK cells in anti-CD40 ligand induced islet allograft tolerance. American Transplant Congress, May 21-25, 2005. Seattle, WA. Am. J. Transplant 5(Suppl 11):279, 2005 (Highlighted in What’s new, What’s hot meeting summary address 90. Beilke, JN, NR Kuhl, RG Gill. A requirement for NK-derived perforin in islet allograft tolerance. American Transplant Congress, May 21-25, 2005. Seattle, WA. Am. J. Transplant 5(Suppl 11):279, 2005 91. Kupfer, TM, ML Crawford, RG Gill. IFN-γ is a key component of CD4 T cell-mediated recurrent autoimmune pathogenesis to islet allografts. American Transplant Congress, May 21-25, 2005. Seattle, WA. Am. J. Transplant 5(Suppl 11):309, 2005 92. RG Gill, K Pham, J Rawson, M Coulombe. B lymphocytes are not required for the induction or maintenance of islet allograft tolerance. American Transplant Congress, May 21-25, 2005. Seattle, WA. Am. J. Transplant 5(Suppl 11):312, 2005 93. Plenter, R.J., AN Doan, TJ Grazia, RG Gill, BA Pietra. Indirect CD4 T-cells mediate cardiac xenograft rejection. American Transplant Congress, May 21-25, 2005. Seattle, WA. Am. J. Transplant 5(Suppl 11):371, 2005 94. Nicolls, MR, T Murakawa, MM Kerklo, RG Gill, FL Grover, MR Zamora. The state of the respiratory epithelium correlates with airway fibrosis in allogeneic orthotopic tracheal transplantation. American Transplant Congress, May 21-25, 2005. Seattle, WA. Am. J. Transplant 5(Suppl 11):441, 2005 95. Sleater, M., AS Diamond, RG Gill. Both direct CD8+ and direct CD4+ T cells reject islet allografts via perforin and FasL/Fas. American Transplant Congress, May 21-25, 2005. Seattle, WA. Am. J. Transplant 5(Suppl 11):480, 2005. 96. Sleater M, Gill RG. Activated donor-MHC class II-restricted CD4+ T cells are sufficient to mediate islet allograft rejection. American Association of Immunologists 2005, Oral Presentation (April, 2005. San Diego, CA). 97. Wiseman, AC, J Beilke, N Kuhl, P Supon, RG Gill. Improved islet cell recovery from donors with a low body mass index: toward making every organ count. American Transplant Congress, May 21-25, 2005. Seattle, WA. Am. J. Transplant 5(Suppl 11):512, 2005 98. Rayat, G, T Kobayashi, G Harb, R Rajotte, G Korbutt, R Gill. Prolonged survival of microencapsulated neonatal porcine islets in mice treated with a combination of anti-CD154 and anti-LFA-1 monoclonal antibodies. 8th International Xenotransplantation Association (IXA) Congress, Sept 10-14, 2005. Goteborg, Sweden. Xenotransplantation 12:398, 2005 99. Nakayama, M., J Beilke, J Jasinski, D Miao, M Kobayashi, L Yu, R Gianani, E Liu, R Gill, G Eisenbarth. Rapid restoration of anti-islet autoimmunity following transplantation of islets with native insulin sequence versus insulin gene knockout islets with mutated B16:A insulin. FOCIS 6th Annul Meeting. June 1-5, 2006. Clin. Immunol. 119(Suppl): S162-3. 100. Nakayama, M, J Beilke, J Jasinski, E Liu, R Gill, G Eisenbarth. The destruction of islets lacking native insulin genes with mutated B16A insulin transgene by diabetic NOD mice. FOCIS 6th Annul Meeting. June 1-5, 2006. Clin. Immunol. 119(Suppl): S171-2, 2006. 101. Kurche, J, JT Hill, SM Weber, J Buhrman, RG Gill. Regulatory CD4+CD25+ T cells restrain alloreactive CD8+ T cells via a shared antigen presenting cell. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 82.

102. Beilke, JN, L Edwards, RG Gill. NK cells restrain CD8 T cells during tolerance induction to islet allografts. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 367. 103. Plenter, RJ, TJ Grazia, KS Hill, JN Beilke, RG Gill, BA Pietra. Anti-LFA-1 induced cardiac allograft tolerance induction requires host MHC class I expression but not CD1-restricted NKT-cells. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 369. 104. Beilke, JN, F Ramirez, RG Gill. Host B7 (CD80/CD86) costimulatory molecules are dispensable for both immunity and tolerance to islet allografts. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 418. 105. Kerklo, MM, RG Gill, AC Wiseman, MR Zamora, MR Nicolls. A determination of human islet viability for transplantation using difference-in-gel electrophoresis (DIGE) proteomics. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 422. 106. Lakey, JRT, J Kaddis, N Ruel, D Quian, RG Gill, F Kandeel, A Naji, A Omer, AO Gaber, MA Hardy, BJ Hering, T Mohanakumar, J Reems, C Ricordi, DR Salomon, GC Weir, JC Niland. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p 573. 107. Plenter, RJ, TJ Grazia, KS Hill, DP Nelson, RG Gill, BA Pietra. Ectopic expression of FasL on cardiomyocytes renders cardiac allografts resistant to rejection by contact-dependent effector CD4+ T-cells. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 603. 108. Sleater, ML, JS Kurche, F Ramirez, RG Gill. Indirect (cross-primed) CD8+ T cells are insufficient to reject islet allografts. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 758. 109. Sleater, ML, SM Weber, RG Gill. Direct (donor MHC-restricted) CD4 T cells are sufficient to mediate the rejection of islet allografts. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 758. 110. Kupfer, TM, RG Gill. NOD antigen-presenting-cells are sufficient to render islets vulnerable to autoimmune injury in an MHC-disparate environment. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 760. 111. Kupfer TM, K Pham, JN Beilke, RG Gill. Acute destruction of islet allografts in NOD mice is donor MHC-independent. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 996. 112. Grazia TJ, RJ Plenter, AN Doan, KS Hill, RG Gill, BA Pietra. Perforin and Fas/FasL form alternate and obligate pathways of CD4+ T cell mediated cardiac allograft rejection. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 1017- 1018. 113. Arefanian G, R Petriw, EB Tredget, RG Gill, RV Rajotte, GS Korbutt, GR Rayat. Species- specific tolerance to neonatal porcine islet xenograft induced by combination of anti-LFA-1 and anti-CD154 monoclonal antibodies. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 1046. 114. Kupfer TM, ML Crawford, RG Gill. IFN-g but not TNFR1 or IL-1R, is a key component of recurrent autoimmune pathogenesis to islet allografts mediated by indirect, islet-autoreactive CD4 T cells. ADA 66th Scientific Sessions. June 22-26, 2006. Chicago IL.

115. Arefanian H, Petriw R, Tredget EB, Gill RG, Rajotte RV, Korbutt GS, Rayat GR. Combination of anti-LFA-1 and anti-CD154 monoclonal antibodies induces tolerance to neonatal porcine islet xenografts. Canadian Society of Transplantation, 2007 Annual Scientific Meeting (March 15-18, Banff, AB). Abstract Book, Page 25 (Abst. #048-B), 2007. 116. Plenter RJ, Grazia TJ, Hill KS, Gill RG, Pietra BA. Cardiac allograft tolerance induction: are host MHC class I expression, CD8+ T-cells, NK cells and NKT-cells required? 2007 American Transplant Congress (San Francisco, CA, May 5-9, 2007). Am. J. Transplant. 7(Suppl. 2):222 (Abst. #290), 2007. 117. Grazia TJ, Plenter RJ, Hill KS, Gill RG, Pietra BA. Spontaneous cardiac allograft tolerance in B71/2-deficient recipients involves peripherally induced CD4+CD25+Foxp3+regulatory T-cells, but does not require thymic-derived endogenous CD4+CD25+Foxp3+ regulatory T- cells. 2007 American Transplant Congress (San Francisco, CA, May 5-9, 2007). Am. J. Transplant. 7(Suppl. 2):488 (Abst. #1330), 2007. 118. Gill RG, Ramirez-Victorino F, Beilke JN. Impairment of long-term islet xenograft survival by both innate (NK) and adaptive (CD8) MHC class I-dependent immunity. 2007 American Transplant Congress (San Francisco, CA, May 5-9, 2007). Am. J. Transplant. 7(Suppl. 2): 582 (Abst. #1691), 2007. (Poster of distinction award) 119. Arefanian H, Petriw R, Tredget E, Gill R, Rajotte R, Rayat G. Combination of anti-LFA-1 and anti-CD154 monoclonal antibodies induces species-specific tolerance to neonatal procine islet xenografts by regulatory T cells. Tom Williams Surgical Research Day, Department of Surgery, University of Alberta (Edmonton, AB, May 11, 2007). Abstract Book, Page 24, 2007. 120. Tucker R, Gill RG, Mack C. Generation of T-cell hybridomas specific for bile duct and Rhesus rotavirus antigens in a murine model of biliary atresia. Immunology 2007, 94th Annual Meeting of the American Association of Immunologists (Miami, FL, May 18-22, 2007). J. Immunol. 178:130.27, 2007. 121. Gill RG. Immunity to pancreatic islet allografts. 2007 CTS-IPITA-IXA 2007 Joint Conference (Minneapolis, MN, September 15-20, 2007). Xenotransplantation 14:397 (Abst. #204.1), 2007. 122. Ramirez-Victorio F, Beilke JN, Gill RG. Both innate and adaptive MHC class I-dependent immunity impair long-term islet xenograft survival. 2007 CTS-IPITA-IXA 2007 Joint Conference (Minneapolis, MN, September 15-20, 2007). Xenotransplantation 14:434-435 (Abst. #407.1), 2007. 123. Kupfer T, Beilke JN, Pham K, Buhrman J, Gill RG. ‘Indirect’ acute islet allograft destruction in NOD mice is independent of donor MHC and requires host B lymphocytes. 2007 CTS-IPITA-IXA 2007 Joint Conference (Minneapolis, MN, September 15-20, 2007). Xenotransplantation 14:435 (Abst. #407.3), 2007. 124. Arefanian H, Tredget EB, Gill RG, Rajotte RV, Rayat GR. Combination of anti-LFA-1 and anti-CD154 monoclonal antibodies induces species-specific tolerance to neonatal porcine islet xenografts by regulatory T cells. 2007 CTS-IPITA-IXA 2007 Joint Conference (Minneapolis, MN, September 15-20, 2007). Xenotransplantation 14:513 (Abst. #PN1404), 2007. 125. Arefanian H, Tredget EB, Gill RG, Rajotte RV, Rayat GR. Induction of tolerance to neonatal porcine islet xenografts using a combination of anti-LFA-1 and anti-CD154 does not require CD4+ or CD8+ T cells. 2007 CTS-IPITA-IXA 2007 Joint Conference (Minneapolis, MN, September 15-20, 2007). Xenotransplantation 14:513 (Abst. #PN1405), 2007.

126. Arefanian H, Tredget EB, Gill RG, Rajotte RV, Rayat GR. Induction tolerance to neonatal porcine islet xenografts using a combination of anti-LFA-1 and anti-CD154 does not require CD4+ or CD8+ T cells. Alberta Diabetes Institute 4th Annual Research Retreat (September 28, 2007, Edmonton, AB). Abstract Book, pg. 20, 2007. 127. Kurche JS, Weber SM, Buhrman JB, Kedi RM, Gill RG. Regulatory T cells from transgenic mice express multiple T cell receptors, confounding studies of their antigen specificity. 13th International Congress of Immunology (Rio de Janeiro, Brasil, August 21-25, 2007). J. Investigative Med. 56:227-228 (Abst. #373), 2008. 128. Arefanian H, Tredget EE, Mok D, Rajotte RV, Gill RG, Korbutt GS, Rayat GR. Combination of anti-LFA-1 and anti-CD154 monoclonal antibodies induces tissue-specific tolerance to neonatal porcine islet xenografts. Tom Williams Surgical Research Day, Department of Surgery, University of Alberta (Edmonton, AB, May 9, 2008). Abstract Book, Page 44, 2008. 129. Arefanian H, Tredget EB, Rajotte RV, Gill RG, Korbutt GS, Rayat GR. Combination of anti-LFA-1 and anti-CD154 monoclonal antibodies induces tissue-specific tolerance to neonatal porcine islet xenografts. XXII International Congress of The Transplantation Society (Sydney, Australia, August 10-14, 2008). Transplantation 86(Suppl 2S):106 (Abst. #299), 2008. 130. Balamurugan AN, Lewis EC, Wiseman AC, Pugazhenthi S, Sarkar SA, Dinarello CA, Gill RG. Effect of in vitro treatment of isolated human islets with human alpha1-antitrypsin. XXII International Congress of The Transplantation Society (Sydney, Australia, August 10- 14, 2008). Transplantation 86(Suppl 2S):445 (Abst. #1320), 2008. 131. Gill RG, Kupfer T, Beilke J, Pham K, Buhrman J. B lymphocyte dependent rejection of islet allografts via indirect recognition in autoimmune-prone NOD mice. XXII International Congress of The Transplantation Society (Sydney, Australia, August 10-14, 2008). Transplantation 86(Suppl 2S):143 (Abst. #405), 2008. 132. Gill RG, Beilke JN, Kuhl NR, Edwards L. NK cells restrain CD8 T cells during tolerance induction to islet allografts. XXII International Congress of The Transplantation Society (Sydney, Australia, August 10-14, 2008). Transplantation 86(Suppl 2S):255 (Abst. #731), 2008. 133. Gill RG, Beilke J. A reappraisal of the passenger leukocyte model of islet allograft immunogeneicity. XXII International Congress of The Transplantation Society (Sydney, Australia, August 10-14, 2008). Transplantation 86(Suppl 2S):448 (Abst. #1330), 2008. 134. Ramirez-Victorino F, Beilke J, Gill RG. Host MHC class I-dependent immunity impairs islet xenograft prolongation. XXII International Congress of The Transplantation Society (Sydney, Australia, August 10-14, 2008). Transplantation 86(Suppl 2S):283 (Abst. #813), 2008. 135. Wang S, Du L, Gill RG. LFA-1 perturbation and transplantation tolerance. Alberta Diabetes Institute Research Day (September 26, 2008, Edmonton, AB). Abstract Book, pg. 17, 2008. 136. Thangavelu G, Gill RG, Anderson CC. Bystander killing of islet cells in an islet transplantation model. Alberta Diabetes Institute Research Day (September 26, 2008, Edmonton, AB). Abstract Book, pg. 32, 2008. 137. Coulombe, M, Toews C, D Mann, L Yu, GS Eisenbarth, RG Gill. Mixed chimerism with MHC-matched, disease resistant bone marrow results in dominant protection from diabetes but not latent disease in NOD mice. 69th Scientific Sessions of the American Diabetes Association (New Orleans, Jun 5-9, 2009). Diabetes 58(Suppl 1):A50, 2009

138. Sklavos, MM, Bertera S, M Coulombe, R Gill, J Crapo, JD Piganelli. Redox modulation protects islets from transplant-induced injury. 69th Scientific Sessions of the American Diabetes Association (New Orleans, Jun 5-9, 2009). Diabetes 58(Suppl 1):A51, 2009 139. Arefanian, H, Q Ramji, RV Rajotte, RG Gill, GS Korbutt, J Rodriguez-Barbosa, GR Rayat. PD-1/PD-1L pathway is required for the induction and maintenance of tolerance to neonatal porcine islet xenografts by combined anti-LFA-1 and anti-CD154 monoclonal antibodies. Joint meeting of the International Pancreas and Islet Transplant Association / International Xenotransplantation Association (Venice, Italy, Oct 12-16, 2009). Xenotransplantation 16:326, 2009. 140. Arefanian, H, Q Ramji, RV Rajotte, RG Gill, GS Korbutt, GR Rayat. Combination of anti- LFA-1 and anti-CD154 monoclonal antibodies induces dominant and CD4+ T cell dependent tolerance to neonatal porcine islet xenografts. Joint meeting of the International Pancreas and Islet Transplant Association / International Xenotransplantation Association (Venice, Italy, Oct 12-16, 2009). Xenotransplantation 16:328-329, 2009 141. Gill, RG, M Coulombe, C Toews, L Yu, GS Eisenbarth. Mixed chimerism with MHC- matched bone marrow transplantation results in dominant protection from autoimmune diabetes. 97th Annual Meeting of the American Association of Immunologists, May 7-11, 2010, Baltimore, MD 142. Arefanian, H., DC Mok, Q Ramji, PW Thompson, C Larsen, RG Gill, GS Korbutt, RV Rajotte, GR Rayat. Immunogencity of islets isolated from three and seven day-old newborn pigs. Transplantation 90(2S):313, 2010. XXIII International Congress of the Transplantation Society, August 16, 2010, Vancouver, Canada 143. Gill, RG, MR Nicolls, A Koh, M Coulombe. Impact of metabolic demand on islet transplant survival and tolerance induction. Transplantation 90(2S):318, 2010. XXIII International Congress of the Transplantation Society, August 16, 2010, Vancouver, Canada

INVITED SPEAKER / MEETING PRESENTATIONS

Invited Speaker: ‘Islet transplantation in the setting of autoimmunity’. Immunology Seminar Series, University of Alabama, Birmingham. December 9, 2010

Invited Speaker: ‘Strategies and challenges for tolerance induction’. University of Wisconsin Transplant Grand Rounds. University of Wisconsin, Madison. November 29, 2010.

Invited Speaker: ‘Strategies and pitfalls for inducing transplant tolerance.’ Plenary Session, 11th Immunology of Diabetes Society Congress, November 3, 2010, Incheon, Korea

Guest Faculty: ‘Linking our understanding of innate and adaptive immunity in transplantation’. American Society of Transplantation, Annual Scientific Exchange, October 21-24, 2010, Orlando, FL

Invited Speaker: ‘Relevance of autoimmunity islet transplantation’. Harvard Medical School / JDRF Center. October 19, 2010. Boston, MA

Invited Speaker: ‘The split personality of pro-inflammatory immunity in transplantation’. Colorado Clinical Scholars Program, September 11, 2010, Aspen, CO

Invited Speaker: ‘Pancreatic islet cell transplantation: have we forgotten about diabetes?’ Colorado Clinical Scholars Program, September 12, 2010, Aspen, CO

Invited Speaker: State of the Art Lecture: ‘Significance of autoimmunity in clinical islet transplantation’ XXIII International Congress of the Transplantation Society, August 16, 2010, Vancouver, Canada

Guest Faculty/Lecturer: ‘Effector cells and injury mechanisms in transplantation’. Post-Graduate Weekend Program, XXII International Congress of the Transplantation Society, August 16, 2010, Vancouver, Canada

Guest Faculty/Lecturer: ‘Beyond T cell suppression’ American Society of Transplantation Fellows Symposium; Basic Science Track. August 8, 2010, Grapevine, TX

Guest Faculty/Lecturer: ‘How is tolerance induced in the graft?’ American Society of Transplantation Fellows Symposium; Basic Science Track. August 8, 2010, Grapevine, TX

Invited Speaker: ‘Immunology of Diabetes: Cliff notes for clinicians’. Management of Diabetes in Youth Conference, July 17, 2010, Keystone, CO

Invited Speaker/Moderator: Grant Writing Workshop for Basic Scientists. American Transplant Congress, May 4, 2010, San Diego, CA

2009 Need to update 2008

Invited Speaker: ‘Ying Yang of pro-inflammatory immunity in transplantation’. Canadian Society of Transplantation Annual Scientific Meeting, Plenary Session 4. March 1, 2008, Mont-Tremblant, Quebec.

Invited Speaker: ‘Beta cell replacement in diabetes: successes and challenges’. J.B. Collip Club, Faculty of Medicine & Dentistry, University of Alberta. March 4, 2008, Edmonton, AB.

Invited Speaker: ‘Immune dysregulation in autoimmune diabetes’. Montreal Diabetes Research Center Seminar Series. March 12, 2008, Montreal, Quebec.

Invited Speaker: ‘Immunology of transplantation’. NSRRC Swine in Biomedical Research Conference. April 3, 2008, San Diego, CA.

Invited Speaker: ‘T cell effector functions in acute rejection’. American Association of Immunologists Experimental Biology 2008. April 5, 2008, San Diego, CA.

Invited Speaker: ‘The varied faces of natural killer cells in transplantation – contributions to both allograft immunity and tolerance’. ISHLT 28th Annual Meeting and Scientific Sessions, Satellite Symposium 4: Innate Immunity and Transplant Rejection. April 9, 2008, Boston, MA.

Invited Speaker: ‘Immune dysregulation in NOD mice’. Muttart Diabetes Research & Training Centre, University of Alberta, April 14, 2008, Edmonton, AB.

Invited Speaker: ‘NK cells and immunomodulation in solid organ transplantation’. VII Congresso Lusobrasileiro de Transplantacao. October 2, 2008, Albufeira, Portugal.

Invited Speaker: ‘The role of cellular cytotoxicity in transplant tolerance and rejection’. Immunology Network Seminar, University of Alberta, October 23, 2008, Edmonton, AB.

Invited Speaker: ‘Immunobiology of islet transplantation’. 4th Canadian Beta Cell Working Group, Montreal Diabetes Research Center, November 15, 2008, Montreal, Quebec.

2007 Invited Speaker: ‘The paradoxical role of pro-inflammatory immunity in allograft tolerance’. Keynote Lecture, Great Lakes Transplant Immunology Forum. Emory University, January 19, 2007, Atlanta, GA.

Invited Speaker: ‘NK cell involvement in transplantation tolerance’. Plenary Lecture, 20th Annual Spring Meeting of the Canadian Society for Immunology. March 17, 2007, Lake Louise, AB.

Invited Speaker: Early Morning Workshop #23 “Innate Immune Mechanisms” – Innate immunity in allograft tolerance. 2007 American Transplant Congress. May 9, 2007, San Francisco, CA.

Invited Speaker: ‘Barriers for immune system evasion: what are we trying to accomplish?’ Biomaterials: Biocompatibility/Tissue Engineering, Gordon Research Conference. July 26, 2007, Holderness, NH.

Invited Speaker: ‘Immunity to pancreatic islet allografts’. CTS, IPITA, IXA 2007 Joint Conference. September 17, 2007, Minneapolis, MN.

Session Chair: “Early Bird Workshop 3: Tailored Immunosuppression.” CTS, IPITA, IXA 2007 Joint Conference. September 18, 2007, Minneapolis, MN.

Session Chair: (C. Mathieu / R.G. Gill): “IPITA 3: ‘Control of Autoimmunity in Pancreas and Islet Transplantation.’ CTS, IPITA, IXA 2007 Joint Conference. September 18, 2007, Minneapolis, MN.

Invited Speaker: ‘The paradox of pro-inflammatory immunity in transplantation tolerance’. Transplant Grand Rounds. “Visiting Professor in Transplantation”, University of California, San Diego. San Diego, California. November 6, 2007.

Invited Speaker: ‘Clinical Islet Transplantation: a work in progress’. Visiting Professor in Transplantation, University of California, San Diego. San Diego, California. November 6, 2007.

Invited Speaker: ‘Post Edmonton - Where do we go from here?’ Transplant Immunology Seminar Series. Sponsored by the Children's Hospital of Philadelphia in conjunction with the University of Pennsylvania School of Medicine, Philadelphia, PA. December 19, 2007.

Invited Speaker : ‘Animal Models to Study Islet Transplantation’. Plenary Lecture, Rachmiel Levine Diabetes and Obesity Symposium. Long Beach, CA. November 10, 2006.

Invited Speaker: ‘Expression and Regulation of Islet Allograft Immunity’. Transplantation Grand Rounds. Thomas E. Starzl Transplantation Institute, University of Pittsburgh. Pittsburgh, PA. September 29, 2006.

Invited Speaker: ‘Expression and Regulation of MHC Class I-Dependent Allograft Immunity’. Harvard Medical School, Transplantation Center. Boston, MA. September 22, 2006.

Invited Speaker: ‘Allo versus Autoimmunity in Islet Transplantation’. Symposium Lecture, World Transplant Congress. Boston, MA. July 24, 2006.

Invited Speaker: ‘Regulation of Graft-Reactive CD8 T-Cells in Allograft Tolerance’. Symposium Lecture. 6th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS). San Francisco, CA. June 3, 2006

Invited Speaker: ‘Role of NK cells in allograft tolerance induction’. NIH / JDRF Workshop on the Role of Innate Immunity in Type I Diabetes. Denver, CO March 21, 2006.

2005 Invited Speaker: ‘Recognition pathways in islet transplant immunity’. Institute for Cellular Therapeutics, University of Kentucky. Louisville, KY. Oct. 18, 2005.

Invited Speaker: ‘Islet allograft immunity: defining the rules of engagement’ Dept. Immunology Retreat, Univ. Colo. Hlth. Sci. Center. Estes Park, CO. Sept. 22, 2005.

Invited Speaker: NOD mice: a model of exuberant indirect allograft immunity. Alberta Diabetes Institute Retreat, University of Alberta. Edmonton, Alberta. Sept. 16, 2005.

Invited Speaker: ‘Prospects and Challenges of Analyzing Transplantation Immunity in Humanized Mouse Models’. NIAID Biodefense Workshop on Humanized Mice. Bethesda Maryland. June 13- 14, 2005.

Invited Speaker: ‘Effector pathways of T cell mediated injury of islet allografts’. American Association of Immunologists (AAI) meeting, American Society of Transplantation Symposium Lecture. San Diego, CA. April 4, 2005.

2004 Invited Speaker: ‘MHC class I directed reactivity in islet allograft immunity and tolerance’. Surgical- Medical Research Institute. University of Alberta, Edmonton, Canada. Nov. 8, 2004.

Invited Speaker: ‘Islet Xenotransplantation’. Plenary Lecture, 5th Annual Rachmiel Levine Diabetes and Obesity Symposium. Los Angeles, CA. October 6-9, 2004.

Invited Speaker: ‘T cell mediated allograft immunity and tolerance’. University of Colorado Health Sciences Center / The Children’s Hospital Hypoplastic Left Heart Syndrome: A Fresh Look. Aspen, CO August 6-8, 2004.

Invited Speaker: ‘The Encapsulated Islet in the Immune Environment’. NIH/JDRF sponsored Symposium: Immunobarriers for Pancreatic Islet Transplantation, Washington D.C., March 29-30, 2004.

2003 Invited Speaker: ‘Islet Allograft Immunity and Tolerance’. Transplant Grand Rounds, University of Michigan, Ann Arbor, Michigan. May 23, 2003.

Invited Speaker: ‘Islet Xenotransplantation: Prospects & Barriers’. Joslin Diabetes Center 2003 Symposium. Evading Beta Cell Death in Diabetes: Prevention and Transplantation. Boston, MA. May 4-6, 2003.

Invited Speaker: JDRF Research Update: ‘Status of Islet Transplantation’. JDRF Southwest Chapter. New Mexico Health Sciences Center. Albuquerque, NM, April 22, 2003.

2002 Invited Speaker: ‘Islet Transplantation, Stem Cells, or Gene Therapy for a Cure’ 14th Annual Diabetes Symposium. Memorial Hospitals Association. Modesto, CA. November 2, 2002.

Invited Speaker: ‘Allo vs Xeno Tolerance’. Symposium Lecture for the 62nd Scientific Sessions of the American Diabetes Association. San Francisco, CA. June 17, 2002.

Invited Speaker: ‘Antigen Presentation Pathways’. Guest Faculty Lecture for Tissue Engineering Post- Graduate Short Course: Biologically-Based Materials for Tissue Engineering. Georgia Institute of Technology. Atlanta, Georgia. March 12, 2002.

2001 Invited Speaker: ‘Cellular Immunity to Immunoisolated Islet Grafts’. NASA/NIDDK/JDRF/NCRR Workshop on Encapsulation & Immunoprotective Strategies of Islet Cells. Washington, DC, December 6-7, 2001. (Also advisor for NIH RFA development for islet encapsulation)

Invited Speaker: ‘Tribute to Kevin J. Lafferty’. Introductory Lecture to the 10th Anniversary Congress, Cell Transplant Society. Keystone, CO. October 14, 2001.

Invited Speaker: ‘Rejection vs. recurrent autoimmunity in pancreas and islet transplantation’. Plenary Lecture at the 8th Congress of the International Pancreas and Islet Transplant Association. Innsbruck, Austria. June 15, 2001.

Invited Speaker: ‘Clinical Pancreatic Islet Transplantation’. UNOS Region 8 Clinical Transplant Forum. Denver, CO. April 26, 2001.

Invited Speaker: ‘Allograft Tolerance’. Medical College of Georgia. Augusta, GA. March 13, 2001.

Invited Speaker: ‘Human islet cell transplantation’. Controversies in Transplantation. Breckenridge, CO. March 9, 2001.

Invited Speaker: ‘Diabetes research update: pancreatic islet transplantation’. Juvenile Diabetes Research Foundation & Humphreys Diabetes Education Center. Boise, Idaho. February 21, 2001.

2000 Invited Speaker: ‘Pathways of T cell recognition of islet transplants’. Scripps Research Institute. La Jolla, CA. December 5, 2000.

Invited Speaker: ‘Analysis of immunoisolation technology with small animal models’. Artificial Organs III, United Engineering Foundation. Davos, Switzerland. October 10, 2000.

Invited Speaker: ‘Mechanisms of islet allograft and xenograft immunity’. Plenary lecture of EASD satellite meeting: Combined islet basic science & transplantation meeting. Eilat, Israel. September 24, 2000.

Invited Speaker: ‘Basis of immunogenicity for endocrine allografts’. 10th International Symposium on Immunobiology of Proteins and Peptides. Tahoe City, California. September 14, 2000.

Invited Speaker: JDF Research Update: Islet Transplantation, Juvenile Diabetes Foundation, Las Vegas Chapter. Las Vegas, NV. June, 29, 2000.

Invited Speaker: ‘Cellular immune response to islet transplants’. Mayo Clinic, Rochester, MN. June 5, 2000.

Invited Speaker: ‘Mechanisms of allo- and xeno-islet cell destruction’. Basic Science Symposium Lecture. . 1st Joint Meeting of the American Society of Transplantation. . 1st Joint Meeting of the American Society of Transplantation. Chicago, IL. May 16, 2000.

Invited Speaker: JDFI: Insulin dependent diabetes research update. JDFI Rocky Mountain Chapter. Denver, CO . April 29, 2000.

1999 Invited Speaker: ‘Paradoxes of pancreatic islet allograft immunity and tolerance’ University of Alberta. Edmonton, Canada. September 17, 1999.

Invited Speaker: ‘Tolerance will work’. Plenary lecture of the International Pancreas and Islet Transplant Society. Sydney, Australia. August 22, 1999.

Invited Speaker: ‘Cellular Immunity and Tolerance to Islet Allografts’. Keystone Symposium, Molecular and Cellular Biology of Transplantation. Lake Tahoe, Nevada, March 21-26, 1999.

1998 Invited Speaker: ‘Transplantation Tolerance’. Anergen, Inc. Redwood City, CA. August 31, 1998

Invited Speaker: ‘Antigen presentation pathways in allograft and xenograft rejection’. Bioartificial Organs II: Technology, Medicine, and Materials. Engineering Foundation, Canmore, Alberta, Canada, July 18-22, 1998.

Invited Speaker: ‘Tolerance to pancreatic islet allografts’. University of Wisconsin-Madison Medical School. Madison, Wisconsin. May 5, 1998.

Invited Speaker: ‘ Pathogenesis of autoimmune diabetes’. University of Wisconsin-Madison Medical School. Madison, Wisconsin. May 4, 1998.

Invited Speaker: ‘Islet Transplantation in Autoimmune Diabetes’. Longwood Area Diabetes/Metabolism Research Seminar Series. Joslin Diabetes Center. Boston, Massachusetts. March 5, 1998.

Invited Speaker: ‘Immunology of Islet Transplantation’. Mini-symposium: Targets of opportunity for treatment and prevention of insulin-dependent diabetes mellitus (IDDM). Boehringer Ingelhein. Ridgefield, Connecticut, January 15, 1998.

1997 Invited Speaker: ‘Human and Animal Islet Transplantation’. Strategic Planning Workshop on Beta-Cell Replacement. Juvenile Diabetes Foundation International & National Aeronautics and Space Administration. Washington, D.C. December 2-3, 1997.

Invited Speaker: ‘Rejection of pancreatic islet allografts mediated by CD8+ T cells’. Cleveland Clinic, Cleveland Ohio. September 5, 1997.

Invited Speaker: JDFI Research Update, Juvenile Diabetes Foundation International, Kansas City Chapter. Kansas City, MO. June 12, 1997.

Invited Speaker: ‘Immunobiology of islet graft rejection’. Symposium lecture, 16th Annual Meeting of the American Society of Transplant Physicians. Chicago, IL. May 13, 1997.

Invited Speaker: ‘T lymphocyte-dependent pathogenesis in islet transplantation ‘. University of Alberta, Department of Surgery. Edmonton, Alberta, Canada. March 17, 1997.

1996 Invited Speaker: ‘Tolerance does not require clonal deletion of antigen-specific T cells’. 15th Plenary Session, Immunology of Diabetes Workshop. Canberra, Australia. December 9, 1996.

Invited Speaker: ‘The role of CD4 T cells in pancreatic islet transplantation immunity’. SmithKline Beecham Pharmaceuticals sponsored Transplantation Symposium. Collegeville, Pennsylvania. May 7, 1996.

Invited Speaker: ‘T cell-dependent pathogenesis in pancreatic islet transplantation’. Alberta Heritage Foundation for Medical Research, University of Alberta, Edmonton, Canada. March 27, 1996.

Invited Speaker: ‘T Cell-Dependent Damage in Pancreatic Islet Transplants’. University of Maryland Medical Center Transplantation Program. Baltimore, Maryland. February 14, 1996.

1995 Invited Speaker: ‘Transplantation Immunity and Tolerance: The Two-Signal Hypothesis Revisited’. Ohio State University College of Medicine Immunology Seminar. The Ohio State University. Columbus, Ohio. November 7, 1995.

Invited Speaker: ‘Immunobiology of Islet Transplantation’. University of Kansas Medical Center. Kansas City, Missouri. October 26, 1995.

Invited Speaker: ‘Pathogenesis of Autoimmune Diabetes’. University of Kansas Medical Center. Kansas City, Missouri. October 25, 1995.

Invited Speaker: ‘Role of Cytokines in Tolerance and Rejection’. Plenary Lecture, Symposium on Tolerance: From Bench to Bedside. Boston, Massachusetts. September 26, 1995.

Invited Speaker: ‘Immune Cellular Effectors/Regulation’. Immune Mechanisms of Cardiovascular Disease. Aspen, Colorado. August 10-12, 1995.

Invited Speaker: ‘The Immunobiology of Islet Transplantation’. Plenary Session of the Fifth Congress of the International Pancreas and Islet Transplantation Association. Miami, Florida. June 22, 1995.

Invited Speaker: ‘The Basis of Tissue Immunogenicity’. University of Minnesota, Dept. of Surgery Transplant Conference. March 2, 1995.

1994 Invited Speaker: ‘Update on Transplantation’. Plenary Session, Management of Pediatric Diabetes, Keystone, Colorado. August 3, 1994.

Invited Speaker: ‘Immunobiology of Cellular Transplantation’. Plenary Session, 2nd International Congress of the Cell Transplantation Society. Minneapolis, Minnesota. May 3, 1994.

1993 Invited Speaker: ‘Pancreatic Islet Xenografting’. Muttart Diabetes Research and Training Centre/ Surgical-Medical Research Institute, University of Alberta, Edmonton, Canada. September 21, 1993.

Invited Speaker: ‘Pancreatic Islet Xenografting’. Diacrin, Inc. Charlestown, Maryland. September 5, 1993.

Invited Speaker: ‘Immunobiology of Pancreatic Islet Xenografting’. Baxter Healthcare Corporation. Chicago, Illinois. May 19, 1993.

Invited Speaker: ‘Islet Cell Xenografting’. Plenary Session of the 12th International Immunology and Diabetes Workshop. Orlando, Florida. April 18, 1993.

Invited Speaker: ‘Lack of peripheral (extrathymic) tolerance induction to pancreatic islet allografts’. Denver Immunology Research Symposium. Denver, Colorado. April 3, 1993.

1992 Invited Speaker: ‘T-T lymphocyte collaboration in islet allograft rejection’. Muttart Diabetes Research and Training Centre/ Surgical-Medical Research Institute, University of Alberta, Edmonton, Canada. April 24, 1992.

1991 Invited Speaker: ‘The role of T lymphocyte subsets in islet graft immunity’. University of Minnesota, Dept. of Surgery Transplant Conference. December 12, 1991.

Invited Speaker: ‘Islet transplantation in Type I Diabetes’. Plenary Session, American Association of Tissue Banks 15th Annual Meeting. Clearwater Beach, Florida. September 30, 1991.

Invited Speaker: ‘T-T collaboration in islet allograft immunity’. DNAX Research Institute of Molecular and Cellular Biology, Inc. Palo Alto, California. February 20, 1991.

Invited Speaker: ‘Role of passenger leukocytes in islet allograft rejection’. Plenary Session, Breckenridge Symposium on Tolerance Induction: Breckenridge, Colorado. January 15-18, 1991.

1990 and prior Invited Speaker: ‘The role of T cell help in pancreatic islet allograft rejection’. University of Florida College of Medicine, Dept. of Pathology, Gainesville, Florida. September 19, 1990.

Invited Speaker: ‘Islet transplantation in Type I diabetes mellitus ‘. Cellular Transplants, Inc. Providence, Rhode Island, March 8, 1990.

Invited Speaker: ‘Role of passenger leukocytes in islet allograft immunity’. Plenary Session of the 2nd International Congress on Pancreatic and Islet Transplantation, Minneapolis, Minnesota, September 22, 1989.

Invited Speaker: ‘Islet cell implantation for diabetes’. Cell Implantation Workshop (Miles Pharmaceuticals). Berkeley, California January 27, 1988.

Invited Speaker: ‘Islet cell transplantation’. Colorado Transplant Symposium. Denver, Colorado, April 14, 1988.

Invited Speaker: ‘Spontaneous animal models of diabetes mellitus: Transplantation in diabetic animals’. (BB and NOD) 38th Annual meeting: American Association of Laboratory Animal Science; Denver, Colorado; November 12, 1987.

CONTRACT RESEARCH FUNDING - CURRENT

o Geron Corporation Title: Characterization and differentiation of human embryonic stem cells into functional pancreatic islets. Principal Investigator: Dr. G. Korbutt (Co-PI) / Dr. R. Gill (Co-PI) Entire Project Period: July 1/08 to June 30/09 Amount: $208,701.00 US

GRANT FUNDING - CURRENT

o Juvenile Diabetes Research Foundation (JDRF 5-2010-628) Type: Innovative Research Title: CD117+ Stem Cells for Facilitating Islet Transplantation Principal Investigator: Ronald G. Gill, PhD Entire Project Period: 09/01/2010-08/31/2011 Year 1 = $100,000 US

o Juvenile Diabetes Research Foundation (JDRF #4-2008-812) Type: Center Grant Title: Project 2 – The interplay between metabolic stress and immune activation in islet transplantation. Principal Investigator: Ronald G. Gill, PhD Entire Project Period: 07/01/2008-06/30/2011 Year 1 = $126,022 US

o Juvenile Diabetes Research Foundation (JDRF #4-2008-812) Type: Center Grant Title: Co-Director – Islet Protection, Regeneration and New Sites for Implantation. Co-Directors: A.M.J. Shapiro, MD and Ronald G. Gill, PhD Entire Project Period: 07/01/2008-06/30/2011 Year 1 = $599,754 US Year 2 = $580,657 US Year 3 = $546,969 US

o Alberta Heritage Foundation for Medical Research (AHFMR) 200700786 Type: Scientist Title: The role of natural killer (NK) cells in transplantation tolerance Principal Investigator: Ronald G. Gill, PhD Entire Project Period: 07/01/2008-06/30/2015 Establishment Grant: $400,000 total amount (start 07/01/2008 – end 06/30/2010) Research Allowance: $350,000 total amount (start 07/01/2008 – end 06/30/2015) Research Prize: $140,000 total amount (start 07/01/2008 – end 06/30/2015) Equipment Amount: $100,000 total amount (start 07/01/2008 – end 06/30/2009)

o Canadian Institutes of Health Research (CIHR 200806RMF-189940-RMC-CBAA-101858) Type: Emerging Team Grant: Regenerative Medicine and Nanomedicine Title: Nanomedicine in organ transplantation: polysaccharide structures as immunologic tolerogens for infant heart transplantation. Principal Investigator: Dr. Lori J. West Role on Project: Ronald G. Gill, PhD, et al. (co-investigators) Entire Project Period: 10//01/2008-09/30/2013 Funding: $404,214 / year

GRANT FUNDING - PAST

o NIH/NIAID 1 U19 AI46374-05 (Kotzin) 5% effort Title: Denver Autoimmunity Center of Excellence Principal Investigator: Brian Kotzin MD Entire Project Period: 09/30/03-03/31/08 Role on Project: Co-investigator Basic Project 2 (Holers) Complement in the Immunopathogenesis of Autoimmune Diabetes- Annual Direct Costs (Project 2): $150,000 Project Description : The major goals of this project are to determine the contribution of complement receptors CR2 and CR1 to the development of  cell injury and diabetes in NOD mice, and to determine the ability of complement inhibitors targeted at C3 activation steps to block the development of  cell injury and diabetes in NOD mice.

o NIH RO1 DK33470 15% effort Title: Reversal of Diabetes by Islet Transplantation Principal Investigator: Ronald G. Gill, PhD Entire Project Period: 4/01/84 - 1/31/07 Annual Direct Costs: $184,500 Project Description: The objective of this proposal is to determine the mechanism of tolerance to pancreatic islet allografts: (1) Determine whether tolerance is dominant or recessive, (2) Determine the requirements for tolerance induction, and (3) Determine the fate of relevant , graft-reactive T cells within a tolerizing environment.

o Source: NIH RO1 DK45773 15% effort Title: Immunobiology or Pancreatic Islet Xenografting Principal Investigator: Ronald G. Gill, PhD Entire Project Period: 1/1/93- 12/31/06 Annual Direct Costs: $132,000 Project Description: The objective of this proposal is to determine the nature of cellular immunity to pancreatic islet xenografts by determining: (1) The basis of cellular rejection triggered by CD4 T cells, and (2) The basis of altered cellular reactivity resulting in long-term xenograft acceptance following anti-LFA-1 (CD11a) therapy.

o Source: NIH RR16599-01 25% effort Title: Islet Cell Resources (ICR) Facility at the University of Colorado Health Sciences Center Principal Investigator: Ronald G. Gill, PhD Entire Project Period: 9/30/01-8/31/06 Annual Direct Costs: $755,000 Project Description : Develop and improve methods of islet harvesting and isolation. Program Official: Richard Knacek Phone: 301-435-0792 E-mail: [email protected]

o Source: NIH R01 HL67976-01 10% effort Title: The mechanism of CD40 T cell dependent acute cardiac allograft rejection Principal Investigator: Biagio A. Pietra Role on Project: Co-Investigator Entire Project Period: 7/1/01 - 6/30/06 Annual Direct Costs: $225,000 Project Description: To clarify the role of CD4 T cells in acute cardiac allograft rejection. Program Official: David Lathrop Phone: 301-435-0504 E-mail [email protected]

o Source: NIH DK/AI 55333 15% effort Title: T cell-mediated injury to islet allografts Principal Investigator: Ronald G. Gill, PhD Entire Project Period: 9/30/02 - 9/29/05 Annual Direct Costs: $143,568 Project Description : The objective of this proposal is to determine the relative effector of mechanisms of CD8-mediated islet allograft immunity and CD4-mediated autoimmune islet injury.

o Source: JDRF 1-2002-127 5% effort Title: Pre-clinical approaches to islet allograft tolerance Principal Investigator: Ronald G. Gill, PhD Entire Project Period: 9/1/02 - 8/31/05 Annual Direct Costs: $123,847 Project Description : The objective of this proposal is to determine the relative capacity of autoimmune-prone NOD mice to pancreatic islet allografts.

o Source: NIH DK57516 5% effort Title: Diabetes and Endocrinology Research Center Principal Investigator: John Hutton, PhD Role on Project: Director, Animal Core Entire Project Period: 6/1/00-3/31/05 Annual Direct Costs: $675,051 Project Description : DERC grant supporting core laboratories. Program Official: Thomas L. Eggerman Phone: 301-594-8813 E-mail [email protected]

o Source: NIH R21 AI 060349-01 10% effort Title: Use of hematopoietic stem cells for the regulation of autoimmune diabetes Principal investigator: Ronald G. Gill, PhD Entire Project Period: 9/30/03 – 8/31/05 Annual Direct Costs: $150,000 Project Description : The goal of this project is to use MHC-matched bone marrow allografts to restore autoimmune propensity and to restore peripheral allograft tolerance defects in autoimmune-prone NOD mice.

o Source: Juvenile Diabetes Foundation 5% effort Title: Manipulation of complement activities as a novel therapeutic strategy for autoimmune IDDM Principal Investigator: V. Michael Holers, MD Role on Project: Co-investigator Entire Project Period: 7/1/99 - 6/30/01 Annual Direct Costs: $90,900 Project Description : The objective of this proposal is to determine the contribution of complement components and receptors in the pathogenesis of autoimmune diabetes.

o Source: Juvenile Diabetes Foundation 10% effort

Title: T lymphocyte-dependent immunity to encapsulated islet allografts Principal Investigator: Ronald G. Gill, PhD Entire Project Period: 9/1/99 - 8/31/01 Annual Direct Costs: $90,909 Project Description : The objective of this proposal is to understand the nature of T lymphocyte- dependent immunity to encapsulated pancreatic islet allografts.

o Source: Juvenile Diabetes Foundation 10% effort Identifying number: #194133 Title: Autoimmune pathogenesis in islet transplants Period of Support: 9/1/94-8/31/96 Annual Direct Costs: $45,031 Role on Project: Principal Investigator

o Source: Juvenile Diabetes Foundation 10% effort Identifying number: #195031 Title: Protection from autoimmune-mediated islet injury through gene therapy Period of Support: 9/1/95-8/31/97 Annual Direct Costs: $45,345 Role on Project: Principal Investigator

o Source: Baxter Healthcare Corporation 5% effort Title: Autoimmune triggering and regulation by immunoisolated islet antigens Period of Support: 7/13/96 - 7/12/97 Role on Project: Principal Investigator Annual Direct Costs: $19,073

o Source: Juvenile Diabetes Foundation 90% effort Identifying number:#291292 Title: Mechanisms of pancreatic islet allograft and xenograft rejection Proposed Period of Support: 7/1/91-6/30/94 Annual Direct Costs: $45,000 Role on Project: Principal Investigator (Career Development Award)

o Source: Juvenile Diabetes Foundation 15% effort Identifying number: #190995 Title: The role of lymphocyte subsets in pancreatic islet graft rejection Period of Support: 9/90-8/92 Annual Direct Costs: $49,286

Role on Project: Principal Investigator

o Source: Juvenile Diabetes Foundation 100% effort Identifying number: #388180 Title: Mechanisms of T-T lymphocyte collaboration in islet allograft immunity. Period of Support: 7/88-6/90 Annual Direct Costs: $27,000 Role on Project: Principal Investigator (fellowship)

o Source: Juvenile Diabetes Foundation 10% effort Identifying number:#18881 Title: Mechanisms of T-T lymphocyte collaboration in islet allograft immunity. Period of Support: 9/88-8/90 Annual Direct Costs: $42,361 Principal Investigator: Kevin J. Lafferty Role on project: co-investigator

TEACHING

1) COURSES / LECTURES

Current

Graduate Courses (University of Alberta) o Course: Surgery 520, University of Alberta; Transplantation Immunology Allograft, 2008/2009 school year (January 29/09) Lectures: 1 hour lecture o Course: Surgery 520, University of Alberta; Transplantation Immunology Xenograft, 2008/2009 school year (February 5/09) Lectures: 1 hour lecture

Graduate Courses (University of Colorado Health Sciences Center) o Course: MICB 7631; The Cell Biology of the Immune System, 1989-90 Lectures: 2 lecture hours on interleukins and cytokine receptors. 2 lecture hours on mechanisms of graft rejection. o Course: MICB 7631; The Cell Biology of the Immune System, 1990 Lectures: 6 lecture hours on cytokines and cytokine receptors. o Course: MICB 7631; The Cell Biology of the Immune System, Winter 1991-1992. Lectures: 6 lecture hours on cytokines and cytokine receptors. o Course: IDPT 7663; Immune response to infectious agents and Immunopathology, Winter 1992- 1993. Lectures: 6 lecture hours on cytokines and cytokine receptors. o Course: IDPT 7664; Immune response to infectious agents and Immunopathology, Spring 1993. Lecture: 2 lecture hours on graft-versus-host-disease. o Course: IMMU 7663; Immune response to infectious agents and Immunopathology, Winter 1993-1994. Lectures: 6 lecture hours on cytokines and cytokine receptors. o Course: IMMU 7664; Immune response to infectious agents and Immunopathology, Spring 1994. Lecture: 4 lecture hours on transplantation. o Course: IMMU 7663; Cell Biology of the Immune System, Winter 1994-1995. Lectures: 6 lecture hours on cytokines and cytokine receptors. o Course: IMMU 7664; Immune response to infectious agents and Immunopathology, Spring 1995. Lecture: 4 lecture hours on transplantation immunology. o Course: IMMU 7663; Cell Biology of the Immune System, Winter 1995-1996. Lectures: 6 lecture hours on cytokines and cytokine receptors. o Course: IMMU 7664; Immune response to infectious agents and immunopathology, Spring 1996. Lecture: 4 lecture hours on transplantation. o Course: IMMU 7663; Cell Biology of the Immune System, Winter 1996-1997. Lectures: 6 lecture hours on cytokines and cytokine receptors. o Immunology Program AMGEN Lecture Series; 2 Lecture hours on transplantation. Boulder, CO. March 21, 1996. o Course: IMMU 7663; Cell Biology of the Immune System, Winter 1997-1998. Lectures: 6 lecture hours on cytokines and cytokine receptors.

o Course: IMMU 7664; 2 Lecture hours on animal models of transplantation, Spring 1998 o Course: IMMU 7662; The Immune Response, Winter 1999-2000. Lectures: 9 lecture hours on costimulation, cytokines, cytokine receptors, host responses to pathogens o Course: IMMU 7663; Advanced Immunolog,y Spring 2000. Lectures: 2 lecture hours on transplantation immunology o Course: IMMU 7663; Advanced Immunolog,y Spring 2000. Lectures: 4 lecture hours on cytokine biology o Course: IMMU 7662; The Immune Response, Winter 2000-2001. Lectures: 7 lecture hours on costimulation, cytokines, cytokine receptors, innate immunity o Course: IMMU 7662; The Immune Response, Winter 2001-2002. Lectures: 9 lecture hours on costimulation, cytokines, cytokine receptors, innate immunity o Course: IMMU 7663; Advanced Immunolog,y Spring 2002. Lectures: 12 lecture hours on costimulation, cytokines, cytokine receptors, antigen presenting cells, transplantation immunology o Course: IMMU 7662; The Immune Response, Winter 2002-2003. Lectures: 1 lecture hour on paradigms in immunology o Course: IMMU 7663; Advanced Immunology, Spring 2003. Lectures: 16 lecture hours on costimulation, cytokines, cytokine receptors, antigen presenting cells, transplantation immunology o Course: IMMU 7663; Advance Immunology, Spring 2004 Lectures: 12 lecture hours on costimulation, cytokines, antigen presenting cells, transplantation o Course: IMMU 7663; Advance Immunology, Spring 2005 Lectures: 14 lecture hours on costimulation, cytokines, antigen presenting cells, transplantation

Course Coordinator (University of Colorado Health Sciences Center) o IMMU 7663; The Immune Response, Winter 1996-1997 o IMMU 7662; The Immune Response, Winter 1997-1999 o MMU 7662; The Immune Response, Winter 1999-2000 o IMMU 7662; The Immune Response, Winter 2000-2001 o IMMU 7662; The Immune Response, Winter 2001-2002 o IMMU 7662; The Immune Response, Winter 2002-2003

Department of Medicine Lectures (University of Colorado Health Sciences Center) o UCHSC Transplantation Immunology Program. September, 1998 o Lectures: 4 hours of introductory lectures on transplantation immunology o Transplantation Tolerance. Pulmonary Division Research in Progress. Sept 24, 1999 o Renal Physiology Course: Lecture on. Transplantation Immunology May 22, 2000 o Transplantation Immunology: The Year in Review UCHSC Association of Transplant Physicians and Surgeons. September, 2000 o Clinical Islet Transplantation UCHSC Association of Transplant Physicians and Surgeons. November, 2000

2) GRADUATE STUDENT SUPERVISION

Current

Supervisor / Thesis Advisor o Selena Wang, 2008-current (PhD, Medical Microbiology & Immunology) o David Al-Adra, 2009-2010 (MSc, Experimental Surgery) o Christian Toso (PhD Exam / Defense) o William Chan (PhD Defense) o Bryce Liang (MSc Defense) o Angela Koh o Troy Baldwin (mentor) o Lillian Du, 2008 (summer student)

Thesis Advisor/Supervisor o Marilyne Coulombe; 1990-1993 (awarded PhD 11/93) (Joint supervision with the University of Alberta) o Leslie Wolf; 1992-1995 (awarded PhD 2/96) o Ricardo Araujo (University of Lisbon, Portugal MSTP Program); 1996-1997 o Megan Crawford, graduate student; 1993-1998 (awarded PhD 12/98) o Andrew Diamond, graduate student (MSTP); 1995-2000 (awarded PhD 12/2000) o Tinalyn Malecki; 1997-2003 (PhD awarded 11/2003) o Zachary Johnson, graduate student; 1999-2004 (Masters awarded 2004) o H. Carl Gelhaus, graduate student; 1999-2004 (PhD awarded 10/2004) o Joshua Beilke, graduate student; 2002-2005 (PhD awarded 11/2005) o Michelle Sleater, graduate student (MSTP); 2001-2006 (PhD awarded 3/2006) o Jonathan Kurche (MSTP); 2005-2007 o Selena Wang, 2008-present, graduate student (University of Alberta) o Adam Burrack, 2010-present, graduate student (University of Colorado)

Graduate Student Thesis Committee o Peg Squier; 1993-1995 o Pamela Smith (Chair); 1994-1997 o Sherry Fleming; 1994-1996 o Michelle Poulin: 1994-2000 o Robert Kelly (Chair); 1998-2000 o Gina Rayat, University of Alberta – External Examiner o Robert Shapiro; 1998-2002 o Kara Lukin; 1998-2004 o Joseph Cantor 1999-2005 o Eli Boritz; 2001-2004 o Jeffery Tessem-Sivert; 2003-present o Kristine Kuhn – 2003-2005 o Amanda Kostyk; 2003-2006 o Sarah J. Lord, University of Alberta – External Examiner o Brian Stadinski (Chair) – 2004 - present

Laboratory Rotation Supervisor o Leslie Miller; 1991 o Dylan Daniel; 1992 o Meagan Scholl; 1993 o Karen Makar; 1994 o Andrew Diamond; 1995 o Nick Craig; 1996 o Tinalyn Malecki; 1997 o Zachary Johnson (BSP); 1999 o Carl Gelhaus; 1999 o Joseph Cantor; 1999 o Michelle Sleater; 2001 o Anatoly Rubtsov, 2002 o Darlynn Korns, 2005 o Lindsay Edwards, 2005 o Jonathan Kurche, 2005 o Jonathan Hill, 2006

Qualifying Examination Committees o Tina Ellis, 1992 o Peg Taylor, 1992 o Angela Dallas, 1993 o Michael Princiotta, 1994 o Lisa Lehman, 1994 o David Poticha, 1994 o Karen Makar, 1995 (Chair) o Mark Hertz, 1995 (Chair) o Dan Fitzsimmons, 1996 (Chair) o John Stolpa, 1996 (Chair) o Robert Kelly, 1997 (Chair) o Murry Wynes, 1997 (Chair) o Juli Moticka, 1998 (Chair) o Gary Shapiro, 1998 (Chair) o Steven J. Kattman, 2000 o Joseph Cantor, 2000 o Dalya Roser, 2000 o Holly Maier, 2001 o Eli Bortiz, 2001 o Kristi Kuhn, 2002 o Daniel Tonkin, 2002 o Anatoly Rubtsov, 2003 o Raedun Clarke, 2003 o Kimberly Mace, 2004 o Jason Oh, 2006 o Corinne Depersis, 2006

3) FELLOWSHIP & FACULTY MENTORING

o Mark Stegall, MD, Department of Surgery, UCHSC. Scientific mentor for Dr. Stegalls American Diabetes Association Career Development Award. 1995-1998. Current position: Professor, Director, Pancreas and Kidney Transplantation, Mayo Clinic, Rochester, MN.

o Biago Pietra, MD, Department of Pediatrics, Division of Cardiology, Children’s Hospital, Denver, CO. Scientific mentor for Dr. Peitras American Hearth Association grant (1995-1996), and NIH KO8 award (1997-2002). Co-investigator on Dr. Pietra’s NIH RO1 award (2003-2007) Current Position: Professor of Pediatrics, Chief of Pediatric Cardiac Transplant Program, The Children’s Hospital and University of Colorado.

o Marilyne Coulombe, PhD Post-doctoral fellow supervisor: (1994-1999). Current Position: Research Associate, University of Colorado Health Sciences Center

o Huan Yang, MD, Regular fellow supervisor: (1994-1997)

o Tul Kalayanamit, MD, Department of Medicine, Pulmonary Division, UCHSC. Scientific Mentor (1996-1998)

o Mark Nicolls, MD, Department of Medicine, Pulmonary Division, UCHSC (1997-2005). Scientific sponsor for Dr. Nicolls NIH K08 award (2000-2005). Current Position: Professor and Chief of Pulmonary Division, Stanford University.

o Alex Wiseman, MD, Department of Medicine, Division of Nephrology, UCHSC (1997-2006). Scientific sponsor for Dr. Wisemans NIH F32 award (1998-2001) and NIH K08 award (2001- present). Currently: Associate Professor of Medicine, Chief of Kidney Transplant Program, University of Colorado

o Gina Rayat, PhD Post-doctoral fellow supervisor (1999-2002) Immunobiology of islet xenotransplantation. Scientific sponsor for JDRF fellowship award Currently: Assistant Professor of Surgery, University of Alberta

o Todd Grazia, MD Assistant professor, Department of Medicine, Pulmonary Division, UCHSC (2002 – present) Scientific sponsor for NIH NRSA fellowship award and NIH KO8 award (2005-2009). Currently: Assistant Professor of Medicine, Pulmonary Division, University of Colorado

o Tinlyn Kupfer, PhD Post-doctoral fellow (2003 –present). Pathogenesis of autoimmune diabetes. Scientific sponsor for ADA Mentored Fellowship Award.

o Sarah Weber, PhD Post-doctoral fellow supervisor (2004-prsent). Regulation of islet transplant rejection by regulatory T cells. Scientific sponsor for JDRF fellowship award.

o Cara Mack, MD Assistant Professor, Department of Medicine. Pathogenesis of biliary atresia. Scientific co-sponsor for NIH KO8 award. Current Position: Associate Professor of Medicine, Gastroenterology Division, University of Colorado

Updated: January 16, 2011